Home • Search • Translate
This article has been published in the peer-reviewed journal WikiJournal of Science (2018). Click to view the published version.
From Wikipedia, the free encyclopedia
ShK domain-like
Rainbow colored cartoon diagram ( N-terminus = blue, C-terminus = red) of an NMR solution structure of the ShK toxin. [1] Sidechains of cysteine residues involved in disulfide linkages are displayed as sticks and the sulfur atoms in these links are colored yellow.
Identifiers
SymbolShK
Pfam PF01549
InterPro IPR003582
SMART SM00254
SCOP2 1roo / SCOPe / SUPFAM
TCDB 8.B.14
OPM superfamily 296
OPM protein 2lg4
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Kappa-stichotoxin-She3a
Identifiers
Organism Stichodactyla helianthus
Symbol?
UniProt P29187
Search for
Structures Swiss-model
Domains InterPro

Stichodactyla toxin (ShK, ShkT) is a 35-residue basic peptide from the sea anemone Stichodactyla helianthus that blocks a number of potassium channels. Related peptides form a conserved family of protein domains known as the ShkT domain. Another well-studied toxin of the family is BgK from Bunodosoma granulifera.

An analogue of ShK called ShK-186 or Dalazatide is in human trials as a therapeutic for autoimmune diseases.

History

A development timeline

Stichodactyla helianthus is a species of sea anemone (Phylum: Cnidaria) belonging to the family Stichodactylidae. Helianthus comes from the Greek words helios meaning sun, and anthos meaning flower, which corresponds to the species' common name "sun anemone". It is sessile and uses potent neurotoxins for defense against its primary predator, the spiny lobster. [2] The venom contains, among other components, numerous ion channel-blocking peptides. In 1995, a group led by Olga Castaneda and Evert Karlsson isolated ShK, a potassium channel-blocking 35-residue peptide from S. helianthus. [3] The same year, William Kem and his collaborator Michael Pennington synthesized and folded ShK, and showed it blocked neuronal and lymphocyte voltage-dependent potassium channels. [4] In 1996, Ray Norton determined the three-dimensional structure of ShK. [1] In 2005–2006, George Chandy, Christine Beeton and Michael Pennington developed ShK-170 and ShK-186 (ShK-L5), selective blockers of Kv1.3. [5] [6] ShK-186, now called Dalazatide, was advanced to human trials in 2015-2017 by Shawn Iadonato and Eric Tarcha, as the first-in-man Kv1.3 blocker for autoimmune disease. [7]

Structure

Clockwise from top-left: NMR solution structure of the ShK toxin; [1] Two views of the surface representation of ShK highlighting basic (blue) and acidic (red) residues; NMR structures of ShK-192, BmK1, MMP23-ShK, and homology model of EWSS-ShK.

ShK is cross-linked by three disulfide bridges: Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32. The solution structure of ShK reveals two short α-helices comprising residues 14-19 and 21–24; the N-terminal eight residues adopt an extended conformation, followed by a pair of interlocking turns that resemble a 310 helix; the C-terminal Cys35 residue forms a nearly head-to-tail cyclic structure through a disulfide bond with Cys3. [1] [8] [9] [10] [11] [12]

Schematic diagram of the primary structure of the ShK peptide highlighting the three disulfide (–S–S–) linkages.

Phylogenetic relationships of ShK and ShK domains

Sequence similarity tree between ShK and related peptides generated with NCBI's Constraint-based Multiple Alignment Tool (COBALT).

The SMART database at the EMBL, as of May 2018, [13] lists 3345 protein domains with structural resemblance to ShK in 1797 proteins (1 to 8 domains/protein), many in the worm Caenorhabditis elegans and venomous snakes. [14] [15] [16] [17] [18] The majority of these domains are in metallopeptidases, whereas others are in prolyl 4-hydroxylases, tyrosinases, peroxidases, oxidoreductases, or proteins containing epidermal growth factor-like domains, thrombospondin-type repeats, or trypsin-like serine protease domains. [14] [15] [16] [17] [18] The only human proteins containing ShK-like domains are MMP-23 (matrix metalloprotease 23) and MFAP-2 (microfibril-associated glycoprotein 2). [14] [15] [16] [17] [18]

Channel targets

Docking configuration of EWSS-ShK in Kv1.3. For clarity, only two of the four Kv1.3 subunits in the tetramer are shown. Lys22 is shown protruding into the pore and interacting with the channel's selectivity filter.

The ShK peptide blocks potassium (K+) ion channels Kv1.1, Kv1.3, Kv1.6, Kv3.2 and KCa3.1 with nanomolar to picomolar potency, and has no effect on the HERG ( Kv11.1) cardiac potassium channel. [19] [20] The neuronal Kv1.1 channel and the T lymphocyte Kv1.3 channel are most potently inhibited by ShK. [8]

Binding configuration in K+ channels

ShK and its analogues are blockers of the channel pore. They bind to all four subunits in the K+ channel tetramer by interacting with the shallow 'vestibule' at the outer entrance to the channel pore. [5] [8] [9] [12] [21] [22] [19] These peptides are anchored in the external vestibule by two key interactions. The first is Lys22, which protrudes into and occludes the channel's pore like a "cork in a bottle" and blocks the passage of potassium ions through the channel pore. [8] [23] [22] [19] The second is the neighboring Tyr23, which together with Lys22 forms a “functional dyad” required for channel block. [8] [9] [22] [23] [19] Many K+ channel-blocking peptides contain such a dyad of a lysine and a neighboring aromatic or aliphatic residue. [19] [20] Some K+ channel-blocking peptides lack the functional dyad, but even in these peptides a lysine physically blocks the channel, regardless of the position of the lysine in the peptide sequence. [24] Additional interactions anchor ShK and its analogues in the external vestibule and contribute to potency and selectivity. [8] [9] [22] [23] [19] For example, Arg11 and Arg29 in ShK interact with two Asp386 residues in adjacent subunits in the mouse Kv1.3 external vestibule (corresponds to Asp433 in human Kv1.3). [8] [9] [22] [23] [19]

IC50 values for block of potassium channels by ShK and related peptides. ND = not done.
Channel ShK(IC50) ShK-186
(IC50) 		ShK-192
(IC50) 		ShK-EWSS
(IC50) 		ShK-F6CA (IC50) ShK-198 (IC50) MMP-23 ShK domain (IC50)
Kv1.1 16-28 pM 7 nM 22 nM 5.4 nM 4 nM 159 pM 49 μM
Kv1.2 10 nM 48 nM ND >100 nM >100 nM ND >100 μM
Kv1.3 10-16 pM 70 pM 140 pM 34 pM 48 pM 41 pM 2.8 μM
Kv1.6 200 pM 18 nM 10.6 nM ND ND ND 400 nM
Kv3.2 5 nM 20 nM 4.2 nM ND ND ND 49 μM
KCa3.1 30 nM 115 nM >100 nM >100 nM ND ND >100 μM

Analogues that block the Kv1.3 channel

Several ShK analogues have been generated to enhance specificity for the Kv1.3 channel over the neuronal Kv1.1 channel and other closely related channels.

  • ShK-Dap22: This was the first analogue that showed some degree of specificity for Kv1.3. The pore-occluding lysine22 of ShK is replaced by diaminopropionic acid (Dap) in ShK-Dap22. [8] [22] [25] Dap is a non-natural lysine analogue with a shorter side chain length (2.5 Å from Cα) than lysine (6.3 Å). [26] Dap22 interacts with residues further out in the external vestibule in contrast to lysine22, which interacts with the channel's selectivity filter. [22] As a consequence, the orientations of ShK and ShK-Dap22 in the external vestibule are significantly different. [22] ShK-Dap22 exhibits >20-fold selectivity for Kv1.3 over closely related channels in whole-cell patch clamp experiments, [8] but in equilibrium binding assays it binds Kv1.1-Kv1.2 heterotetramers with almost the same potency as ShK, which is not predicted from the study of homotetrameric Kv1.1 or Kv1.2 channels. [25]
  • ShK-F6CA: Attaching a fluorescein to the N-terminus of the peptide via a hydrophilic AEEA linker (2-aminoethoxy-2-ethoxy acetic acid; mini-PEG) resulted in a peptide, ShK-F6CA (fluorescein-6-carboxyl), with 100-fold specificity for Kv1.3 over Kv1.1 and related channels. [27] Attachment of a tetramethylrhodamine or a biotin via the AEEA linker to ShK's N-terminus did not increase specificity for Kv1.3 over Kv1.1. [27] The enhanced specificity of ShK-F6CA might be explained by differences in charge: F6CA is negatively charged; tetramethylrhodamine is positively charged; and biotin is neutral. [27] Subsequent studies with other analogues suggest that the negatively charged F6CA likely interacts with residues on the turret of the Kv1.3 channel as shown for ShK-192 and ShK-EWSS. [9] [12]
  • ShK-170, ShK-186, ShK-192 and ShK-EWSS: Based on ShK-F6CA, additional analogues were made. Attaching a L- phosphotyrosine to the N-terminus of ShK via an AEEA linker resulted in a peptide, ShK-170, with 100-1000-fold specificity for Kv1.3 over related channels. ShK-186 (a.k.a. SL5; a.k.a. Dalazatide) is identical to ShK-170 except the C-terminal carboxyl is replaced by an amide. ShK-186 blocks Kv1.3 with an IC50 of 69 pM and exhibits the same specificity for Kv1.3 over closely related channels as ShK-170. [19] The L-phosphotyrosine of ShK-170 and ShK-186 rapidly gets dephosphorylated in vivo generating an analogue, ShK-198, with reduced specificity for Kv1.3. [5] [28] [29] To overcome this problem, ShK-192 and ShK-EWSS were developed. In ShK-192, the N-terminal L-phosphotyrosine is replaced by a non-hydrolyzable para-phosphonophenylalanine (Ppa), and Met21 is replaced by the non-natural amino acid norleucine to avoid methionine oxidation. [9] [29] In ShK-EWSS, the AEEA linker and L-phosphotyrosine are replaced by the residues glutamic acid (E), tryptophan (W) and two serines (S). [12] Both ShK-192 and ShK-EWSS are highly specific for Kv1.3 over related channels.
  • ShK-K18A: Docking and molecular dynamics simulations on Kv1.3 and Kv1.1 followed by umbrella sampling simulations, paved the way to the selective Kv1.3 inhibitor ShK-K18A. [30]
  • ShK-related peptides in parasitic worms: AcK1, a 51-residue peptide from hookworms Ancylostoma caninum and Ancylostoma ceylanicum, and BmK1, the C-terminal domain of a metalloprotease from filarial worm Brugia malayi, adopt helical structures closely resembling ShK. [31] AcK1 and BmK1 block Kv1.3 channels at nanomolar-micromolar concentrations, and they suppress rat effector memory T cells without affecting naïve and central memory T cell subsets. [31] Further, they suppress IFN-g production by human T cells and they inhibit the Delayed-type hypersensitivity response caused by skin-homing effector memory T cells. [31] Teladorsagia circumcincta is an economically important parasite that infects sheep and goats. TcK6, a 90-residue protein with a C-terminal ShK-related domain, is upregulated during the mucosal dwelling larval stage of this parasite. [32] TcK6 causes modest suppression of thapsigargin-triggered IFN-g production by sheep T cells, suggesting that the parasite use this protein for immune evasion by modulating mucosal T cells. [32]

Extending circulating half-life

Due to their low molecular mass, ShK and its analogues are prone to rapid renal elimination. In rats, the half-life is ~6 min for ShK-186 and ~11 min for ShK-198, with a clearance rate of ~950 ml/kg·min. [28] In monkeys, the half-life is ~12 min for ShK-186 and ~46 min for ShK-198, with a clearance rate of ~80 ml/kg·min. [28]

PEGylation of ShK: Conjugation of polyethylene glycol (PEG) to ShK[Q16K], an ShK analogue, increased its molecular mass and thereby reduced renal clearance and extended plasma half-life to 15 h in mice and 64 h in cynomolgus monkeys. [11] PEGylation can also decrease immunogenicity and protect a peptide from proteolysis and non-specific adsorption to inert surfaces. PEGylated ShK[Q16K] prevented adoptive-transfer experimental autoimmune encephalomyelitis in rats, a model for multiple sclerosis. [11]

  • Conjugation of ShK to larger proteins: The circulating half-life of peptides can be prolonged by coupling them to larger proteins or protein domains. [19] [33] [34] By screening a combinatorial ShK peptide library, novel analogues were identified, which when fused to the C-termini of IgG1-Fc retained picomolar potency, effectively suppressed in vivo delayed type hypersensitivity and exhibited a prolonged circulating half-life. [35]
  • Prolonged effects despite rapid plasma clearance: SPECT/CT imaging studies with a 111In-DOTA-conjugate of ShK-186 in rats and squirrel monkeys revealed a slow release from the injection site and blood levels above the channel blocking dose for 2 and 7 days, respectively. [28] Studies on human peripheral blood T cells showed that a brief exposure to ShK-186 was sufficient to suppress cytokine responses. [28] These findings suggest that ShK-186, despite its short circulating half-life, may have a prolonged therapeutic effect. In rats, the peptide is effective in treating disease in animal models of autoimmune diseases when administered once a day to once in 3 days. [28] In humans, subcutaneous injections twice a week are sufficient to ameliorate disease in patients with plaque psoriasis. [7]

Peptide delivery

The low molecular mass of ShK and its analogues, combined with their high isoelectric points, makes it unlikely that these peptides will be absorbed from the stomach or intestine following oral administration. Sub-lingual delivery is a possibility. A fluorescent ShK analogue was absorbed into the blood stream at pharmacological concentrations following sublingual administration with a mucoadhesive chitosan-based gel, with or without the penetration enhancer cetrimide. [36] Delivery of the peptide as an aerosol through the lung, or across the skin, or as eye drops are also possibilities. [37] [38] [39]

Modulation of T cell function

Expression of Kv1.3 and KCa3.1 channels during T cell activation and memory T cell generation. The numbers represent functional channel numbers per T cell determined by whole cell patch clamp. The effect of specific blockade of Kv1.3 or KCa3.1 on T cell proliferation is shown. TCM = Central memory T cell. TEM = Effector memory T cell. TEMRA = Effector memory T cell that has reacquired CD45RA.

During T cell-activation, calcium enters lymphocytes through store-operated CRAC channels (calcium release activated channel) formed as a complex of Orai and Stim proteins. [40] [41] The rise in intracellular calcium initiates a signaling cascade culminating in cytokine production and proliferation. [40] [41] The Kv1.3 K+ channel and the calcium-activated KCa3.1 K+ channel in T cells promote calcium entry into the cytoplasm through CRAC by providing a counterbalancing cation efflux. [19] [40] [41] Blockade of Kv1.3 depolarizes the membrane potential of T cells, suppresses calcium signaling and IL-2 production, but not IL2-receptor expression. [42] [43] [44] [45] [46] Kv1.3 blockers have no effect on activation pathways that are independent of a rise in intracellular calcium (e.g. anti-CD28, IL-2). [42] [43] Expression of the Kv1.3 and KCa3.1 channels varies during T cell activation and differentiation into memory T cells. [19] [40] [41] [47] [48] When naïve T cells and central memory T cells (TCM) are activated they upregulate KCa3.1 expression to ~500 per cell without significant change in Kv1.3 numbers. [19] [40] [41] [47] [48] In contrast, when terminally differentiated effector memory subsets (TEM, TEMRA [T effector memory re-expressing CD45RA]) are activated, they upregulate Kv1.3 to 1500 per cell without changes in KCa3.1. [19] [40] [41] [47] [48] The Kv1.3 channel number increases and the KCa3.1 channel number decreases as T cells are chronically activated. [40] [41] [47] [48] [49] As a result of this differential expression, blockers of KCa3.1 channels preferentially suppress the function of naïve and TCM cells, while ShK and its analogues that selectively inhibit Kv1.3 channels preferentially suppress the function of chronically activated effector memory T cells (TEM, TEMRA). [19] [40] [41] [47] [48]

Of special interest are the large number of ShK analogues developed at Amgen that suppressed interleukin-2 and interferon gamma production by T cells. [11] This inhibitory effect of Kv1.3 blockers is partial and stimulation strength dependent, with reduced inhibitory efficacy on T cells under strengthened anti-CD3/CD28 stimulation. [50] Chronically activated CD28null effector memory T cells are implicated in autoimmune diseases (e.g. lupus, Crohn's disease, rheumatoid arthritis, multiple sclerosis). [51] [52] [53]

Blockade of Kv1.3 channels in these chronically activated T cells suppresses calcium signaling, cytokine production (interferon gamma, interleukin-2, interleukin 17), and cell proliferation. [6] [19] [29] [30] [40] [41] [47] [48] Effector memory T cells that are CD28+ are refractory to suppression by Kv1.3 blockers when they are co-stimulated by anti-CD3 and anti-CD28 antibodies, but are sensitive to suppression when stimulated by anti-CD3 antibodies alone. [48] In vivo, ShK-186 paralyzes effector-memory T cells at the site of an inflammatory delayed type hypersensitivity response and prevents these T cells from activating in the inflamed tissue. [54] In contrast, ShK-186 does not affect the homing and motility of naive and TCM cells to and within lymph nodes, most likely because these cells express the KCa3.1 channel and are therefore protected from the effect of Kv1.3 blockade. [54]

Effects on microglia

Kv1.3 plays an important role in microglial activation. [55] [56] [57] [58] ShK-223, an analogue of ShK-186, decreased lipopolysaccharide (LPS) induced focal adhesion formation by microglia, reversed LPS-induced inhibition of microglial migration, and inhibited LPS-induced upregulation of EH domain containing protein 1 (EHD1), a protein involved in microglia trafficking. [59] Increased Kv1.3 expression was reported in microglia in Alzheimer plaques. [60] Kv1.3 inhibitors may have use in the management of Alzheimer's disease, as reported in a proof-of-concept study in which a small molecule Kv1.3 blocker (PAP-1) alleviated Alzheimer's disease-like characteristics in a mouse model of AD. [61]

Efficacy of analogues in animal models of human diseases

Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis

ShK, ShK-Dap22, ShK-170 and PEGylated ShK-Q16K prevent adoptive-transfer EAE in Lewis rats, a model of multiple sclerosis. [5] [11] Since multiple sclerosis is a relapsing-remitting disease, ShK-186 and ShK-192 were evaluated in a relapsing-remitting EAE model in DA (Dark Agouti) rats. Both prevented and treated disease when administered once a day to once in three days. [54] [28] [29] Thus, Kv1.3 inhibitors are effective in treating disease in rat models of multiple sclerosis when administered alone, [11] [28] [62] [63] and therapeutic effectiveness does not appear to be compromised by compensatory over-expression of KCa3.1 channels. [49] [64]

Pristane-induced arthritis (PIA), a model for rheumatoid arthritis

ShK-186 was effective in treating PIA when administered every day or on alternate days. [5] [6] [54] [28] A scorpion toxin inhibitor of KV1.3 was also effective in this model. [65] In both these studies, blockade of Kv1.3 alone was sufficient to ameliorate disease and simultaneous blockade of KCa3.1 was not necessary as has been suggested. [49] [64]

Rat models of atopic dermatitis

Most infiltrating T-cells in skin lesions from patients with moderate-to-severe atopic dermatitis (AD) express high levels of Kv1.3, suggesting that inhibitors of Kv1.3 may be effective in treating AD. [66] Ovalbumin-induced delayed type hypersensitivity and oxazolone-induced dermatitis are considered to be models of atopic dermatitis. [66] [67] [68] [69] [70] ShK, ShK-170, ShK-186, ShK-192 and ShK-IgG-Fc were all effective in the ovalbumin-induced delayed type hypersensitivity model, [5] [6] [9] [54] [28] [29] [35] [66] [69] [70] [71] [72] [73] [74] [75] while a topical formulation of ShK-198 was effective in treating oxazolone-induced dermatitis. [66] Even where compensation by KCa3.1 channels was reported to over-ride KV1.3 block, ShK administered alone suppressed delayed type hypersensitivity significantly in 2 of 3 studies, albeit modestly. [49]

Psoriasis

Psoriasis is a severe autoimmune disease of the skin that afflicts many people worldwide. Despite the success of recent biologics in ameliorating disease, there is still a search for safe and effective drugs for psoriasis. KV1.3 inhibitors (ShK, PAP-1) have been reported to treat disease in psoriasiform (psoriasis-like) SCID (severe combined immunodeficiency) mouse model. [76] In a Phase 1b placebo-controlled clinical study in patients with plaque psoriasis, ShK-186 administered twice a week (30 or 60 mg/dose/patient) by subcutaneous injection caused improvements with a statistically significant reduction in their PASI (Psoriasis Area and Severity Index) score between baseline and day 32. [7] These patients also exhibited reduced plasma levels of multiple inflammation markers and decreased expression of T cell activation markers on peripheral blood memory T cells. [7]

Diet-induced obesity and fatty liver disease

Obesity and diabetes are major healthcare problems globally. There is need for safe drugs for these metabolic diseases. In a mouse model of diet-induced obesity, ShK-186 counteracted the negative effects of increased caloric intake. It reduced weight gain, adiposity, and fatty liver; decreased blood levels of cholesterol, sugar, HbA1c, insulin, and leptin; and enhanced peripheral insulin sensitivity. [77] Genetic deletion of the Kv1.3 gene has the same effect, indicating that ShK-186's effect is due to Kv1.3 blockade. [78] [77] [79] [80] At least two mechanisms contribute to ShK-186's therapeutic benefits. The high calorie diet induced Kv1.3 expression in brown fat tissues. [77] By blocking Kv1.3, ShK-186 doubled glucose uptake and increased β-oxidation of fatty acids, glycolysis, fatty acid synthesis and uncoupling protein 1 expression by brown fat. [77] As a consequence of brown fat activation, oxygen consumption and energy expenditure were augmented. [77] The obesity diet also induced Kv1.3 expression in the liver, and ShK-186 caused profound alterations in energy and lipid metabolism in the liver. ShK, its analogues or other Kv1.3 blockers may have use in controlling the negative consequences of high calorie diets.

Arousal and anesthesia

The mechanisms of general anesthesia involve multiple molecular targets and pathways that are not completely understood. [81] Sevoflurane is a common anesthetic used to induce general anesthesia during surgery. [81] Rats continually exposed to sevoflurane lose their righting reflex as an index of loss of consciousness. In these rats, microinfusion of ShK into the central medial thalamic nucleus (CMT) reversed sevoflurane-induced anesthesia in rodents. [81] ShK-treated rats righted themselves fully (restored consciousness) despite being continually exposed to sevoflurane. [81] ShK-microinfusion into neighboring regions of the brain did not have this effect. [81] Sevoflurane enhanced potassium currents in the CMT, while ShK and ShK-186 countered this effect. [81] These studies suggest that ShK-sensitive K+ channels in the CMT are important for suppressing arousal during anesthesia.

Preventing brain damage following therapeutic brain radiation

Brain radiation is used to treat tumors of the head, neck, and brain, but this treatment carries a significant risk of neurologic injury. Injury is, in part, due to the activation of microglia and microglia-mediated damage of neurons. Neuroprotective therapies for radiation-induced brain injury are still limited. In a mouse model of brain radiation, ShK-170 reversed neurological deficits, and protected neurons from radiation-induced brain injury by suppressing microglia. [82]

Toxicity of ShK and its analogues

ShK and ShK-Dap22

ShK peptide has a low toxicity profile in mice. ShK is effective in treating autoimmune diseases at 10 to 100 mg/kg bodyweight. It has a median paralytic dose of approximately 25 mg/kg bodyweight (250-2500 higher than the pharmacological dose). In rats the therapeutic safety index is greater than 75-fold. ShK-Dap22 displayed a lower toxicity profile. [8] A 1.0 mg dose did not induce any hyperactivity, seizures or mortality in rats. The median paralytic dose for ShK-Dap22 is about 200 mg/kg bodyweight (2000-20000 higher than pharmacological dose). [8] PEGylated ShK[Q16K] showed no adverse toxicity in monkeys over a period of several months. [11]

ShK-186/Dalazatide

ShK-186 also displays a low toxicity profile in rats. Daily administration of ShK-170 or ShK-186 (100 µg/kg/day) by subcutaneous injection over 4 weeks in rats does not induce any changes in blood counts, blood chemistry or histopathology. [5] [6] [28] By virtue of suppressing only TEM and TEMRA cells, ShK-186 did not compromise protective immune responses to influenza virus and chlamydial infection in rats, most likely because naïve and TCM cells unaffected by Kv1.3 blockade mounted effective immune responses. [54] ShK-186 is poorly immunogenic and did not elicit anti-ShK antibodies in rats repeatedly administered the peptide. [6] This is possibly because the peptide's disulfide-bonded structure hinders processing and antigen presentation by antigen-presenting cells. ShK-186 also shares sequence and structural similarity to a ShK-like domain in matrix metalloprotease 23, [14] [15] [16] [17] [18] which may cause the immune system to assume it is a normal protein in the body. ShK-186 was safe in non-human primates. In Phase 1a and 1b trials in healthy human volunteers, ShK-186 was well tolerated, no grade 3 or 4 adverse effects or laboratory abnormalities were noted, and the predicted range of drug exposures were achieved. [7] The most common adverse events were temporary mild (Grade 1) hypoesthesia and paresthesia involving the hands, feet, or perioral area. Mild muscle spasms, sensitivity of teeth, and injection site pain were also observed. [7]

Functions of ShK-like proteins

MMP-23

MMP-23 belongs to the family of zinc- and calcium-dependent matrix metalloproteases. It is anchored in the cell membrane by an N-terminal prodomain, and it contains three extracellular domains: catalytic metalloprotease domain, ShK domain and immunoglobulin-like cell adhesion molecule ( Ig-CaM) domain. [14] [15] [16] [17] [18] The prodomain traps the voltage-gated potassium channel KV1.3, but not the closely related KV1.2 channel, in the endoplasmic reticulum. [14] [15] [16] [17] Studies with chimeras suggest that the prodomain interacts with the KV1.3 region from the S5 transmembrane segment to the C terminus. [14] [15] [16] [17] NMR studies of the prodomain reveal a single trans-membrane alpha-helix, joined by a short linker to a juxta-membrane alpha-helix, which is associated with the surface of the membrane. [14] [15] [16] [17] The prodomain shares topological similarity with proteins (KCNE1, KCNE2, KCNE4) known to trap potassium channels in the secretory pathway, suggesting a shared mechanism of channel regulation. [14] [15] [16] [17] MMP-23's catalytic domain displays structural homology with catalytic domains in other metalloproteases, and likely functions as an endopeptidase. MMP-23's ShK domain lies immediately after the catalytic domain and is connected to the IgCAM domain by a short proline-rich linker. It shares phylogenetic relatedness to sea anemone toxins and ICR-CRISP domains, being most similar to the BgK toxin from sea anemone Bunodosoma granulifera. [14] [15] [16] [17] This ShK domain blocks voltage-gated potassium channels (KV1.6 > KV1.3 > KV1.1 = KV3.2 > Kv1.4, in decreasing potency) in the nanomolar to low micromolar range. [14] KV1.3 is required for sustaining calcium signaling during activation of human T cells. [19] [40] [47] By trapping KV1.3 in the endoplasmic reticulum via the prodomain, and by blocking the KV1.3 channel with the ShK domain, MMP-23 may serve as an immune checkpoint to reduce excessive T cell activation during an immune response. In support, increased expression of MMP-23 in melanoma cancer cells decreases tumor-infiltrating lymphocytes, and is associated with cancer recurrence and shorter periods of progression-free survival. [17] However, in melanomas, expression of MMP-23 does not correlate with Kv1.3 expression, suggesting that MMP-23's deleterious effect in melanomas may not be connected with its Kv1.3 channel-modulating function. [17] MMP-23's C-terminal IgCAM domain shares sequence similarity with IgCAM domains in proteins known to mediate protein-protein and protein-lipid interactions (e.g. CDON, human Brother of CDO, ROBO1-4, hemicentin, NCAM1 and NCAM2). [14] [15] [16] [17] In summary, the four domains of MMP-23 may work synergistically to modulate immune responses in vivo.

Mab7

In male Caenorhabditis elegans worms, the absence of a protein called Mab7 ( Q95Q39) results in malformed sensory rays that are required for mating. [63] Introduction of Mab7 into these male worms restores normal development of normal sensory rays. [63] Introduction of Mab7 proteins lacking the ShK domain does not correct the defect of sensory rays, suggesting a role for the ShK-domain of Mab7 in sensory ray development. [63]

HMP2 and PMP1

HMP2 and PMP-1 are astacin metalloproteinases from the Cnidarian Hydra vulgaris and the jellyfish Podocoryne carnea that contain ShK-like domains at their C-termini. [83] [17] Both these ShK-domains contain the critical pore-occluding lysine required for K+ channel block. [14] HMP2 plays a critical role in foot regeneration of Hydra, [83] while PMP-1 is found in the feeding organ of the jelly fish and the ShK-domain may paralyze prey after they are ingested. [17]

CRISPs

The two domains of a Cysteine-rich secretory protein (CRISP). [84] CAP-like 'Pathogenesis-related 1' domain (PR-1) in white. ShK-like 'Cysteine-Rich Domain' (CRD) in red. Disulphides in yellow. ( PDB: 1WVR​)

More distantly related are Cysteine-rich secretory proteins (CRISPs), which contain a ShK-like 'Cystine-rich domain' as well as a larger CAP-like 'Pathogenesis related 1' domain. [84] These proteins are involved in mammalian reproduction [85] as well as in the venoms of some snakes. [86] In both cases, the mechanism is believed to involve inhibition of ion channel activity. [85]

References

This article was adapted from the following source under a CC BY 4.0 license ( 2018) ( reviewer reports): Shih Chieh Chang; Saumya Bajaj; K. George Chandy (1 June 2018). "ShK toxin: history, structure and therapeutic applications for autoimmune diseases" (PDF). WikiJournal of Science. 1 (1): 3. doi: 10.15347/WJS/2018.003. ISSN  2470-6345. Wikidata  Q55120296.{{ cite journal}}: CS1 maint: unflagged free DOI ( link)

  1. ^ a b c d PDB: 1ROO​; Tudor JE, Pallaghy PK, Pennington MW, Norton RS (April 1996). "Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone". Nature Structural Biology. 3 (4): 317–20. doi: 10.1038/nsb0496-317. PMID  8599755. S2CID  9180663.
  2. ^ Norton RS, Pennington MW, Wulff H (December 2004). "Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases". Current Medicinal Chemistry. 11 (23): 3041–52. doi: 10.2174/0929867043363947. PMID  15578998.
  3. ^ Castañeda O, Sotolongo V, Amor AM, Stöcklin R, Anderson AJ, Harvey AL, Engström A, Wernstedt C, Karlsson E (May 1995). "Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus". Toxicon. 33 (5): 603–13. doi: 10.1016/0041-0101(95)00013-C. PMID  7660365.
  4. ^ Pennington MW, Byrnes ME, Zaydenberg I, Khaytin I, de Chastonay J, Krafte DS, Hill R, Mahnir VM, Volberg WA, Gorczyca W (November 1995). "Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone". International Journal of Peptide and Protein Research. 46 (5): 354–8. doi: 10.1111/j.1399-3011.1995.tb01068.x. PMID  8567178.
  5. ^ a b c d e f g Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG (April 2005). "Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases". Molecular Pharmacology. 67 (4): 1369–81. doi: 10.1124/mol.104.008193. PMC  4275123. PMID  15665253.
  6. ^ a b c d e f Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–9. Bibcode: 2006PNAS..10317414B. doi: 10.1073/pnas.0605136103. PMC  1859943. PMID  17088564.
  7. ^ a b c d e f Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP (July 2017). "Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial". PLOS ONE. 12 (7): e0180762. Bibcode: 2017PLoSO..1280762T. doi: 10.1371/journal.pone.0180762. PMC  5516987. PMID  28723914.
  8. ^ a b c d e f g h i j k Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Christian EP, Cahalan MD, Norton RS, Chandy KG (December 1998). "ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide". The Journal of Biological Chemistry. 273 (49): 32697–707. doi: 10.1074/jbc.273.49.32697. PMID  9830012.
  9. ^ a b c d e f g h Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG (April 2009). "Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes". Molecular Pharmacology. 75 (4): 762–73. doi: 10.1124/mol.108.052704. PMC  2684922. PMID  19122005.
  10. ^ Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS (November 2012). "A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3". FEBS Letters. 586 (22): 3996–4001. doi: 10.1016/j.febslet.2012.09.038. PMC  3496055. PMID  23063513.
  11. ^ a b c d e f g Murray JK, Qian YX, Liu B, Elliott R, Aral J, Park C, Zhang X, Stenkilsson M, Salyers K, Rose M, Li H, Yu S, Andrews KL, Colombero A, Werner J, Gaida K, Sickmier EA, Miu P, Itano A, McGivern J, Gegg CV, Sullivan JK, Miranda LP (September 2015). "Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3". Journal of Medicinal Chemistry. 58 (17): 6784–802. doi: 10.1021/acs.jmedchem.5b00495. PMID  26288216. S2CID  28397762.
  12. ^ a b c d Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS (June 2015). "N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3". The FEBS Journal. 282 (12): 2247–59. doi: 10.1111/febs.13294. PMC  4472561. PMID  25864722.
  13. ^ "SMART: ShKT domain annotation". smart.embl-heidelberg.de. Retrieved 2018-05-16.
  14. ^ a b c d e f g h i j k l m Rangaraju S, Khoo KK, Feng ZP, Crossley G, Nugent D, Khaytin I, Chi V, Pham C, Calabresi P, Pennington MW, Norton RS, Chandy KG (March 2010). "Potassium channel modulation by a toxin domain in matrix metalloprotease 23". The Journal of Biological Chemistry. 285 (12): 9124–36. doi: 10.1074/jbc.M109.071266. PMC  2838332. PMID  19965868.
  15. ^ a b c d e f g h i j k Nguyen HM, Galea CA, Schmunk G, Smith BJ, Edwards RA, Norton RS, Chandy KG (March 2013). "Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease". The Journal of Biological Chemistry. 288 (9): 6451–64. doi: 10.1074/jbc.M112.421495. PMC  3585079. PMID  23300077.
  16. ^ a b c d e f g h i j k Galea CA, Nguyen HM, George Chandy K, Smith BJ, Norton RS (April 2014). "Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking". Cellular and Molecular Life Sciences. 71 (7): 1191–210. doi: 10.1007/s00018-013-1431-0. PMID  23912897. S2CID  8113220.
  17. ^ a b c d e f g h i j k l m n o Moogk D, da Silva IP, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krogsgaard M (December 2014). "Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy". Journal of Translational Medicine. 12: 342. doi: 10.1186/s12967-014-0342-7. PMC  4272770. PMID  25491880.
  18. ^ a b c d e Pan T, Gröger H, Schmid V, Spring J (July 1998). "A toxin homology domain in an astacin-like metalloproteinase of the jellyfish Podocoryne carnea with a dual role in digestion and development". Development Genes and Evolution. 208 (5): 259–66. doi: 10.1007/s004270050180. PMID  9683741. S2CID  13562676.
  19. ^ a b c d e f g h i j k l m n o p Chandy KG, Norton RS (June 2017). "v1.3 channels in T cells as therapeutics for autoimmune disease". Current Opinion in Chemical Biology. 38: 97–107. doi: 10.1016/j.cbpa.2017.02.015. PMID  28412597.
  20. ^ a b Gilquin B, Braud S, Eriksson MA, Roux B, Bailey TD, Priest BT, Garcia ML, Ménez A, Gasparini S (July 2005). "A variable residue in the pore of Kv1 channels is critical for the high affinity of blockers from sea anemones and scorpions". The Journal of Biological Chemistry. 280 (29): 27093–102. doi: 10.1074/jbc.M413626200. PMID  15890656.
  21. ^ Pennington MW, Mahnir VM, Khaytin I, Zaydenberg I, Byrnes ME, Kem WR (December 1996). "An essential binding surface for ShK toxin interaction with rat brain potassium channels". Biochemistry. 35 (51): 16407–11. doi: 10.1021/bi962463g. PMID  8987971.
  22. ^ a b c d e f g h Lanigan MD, Kalman K, Lefievre Y, Pennington MW, Chandy KG, Norton RS (October 2002). "Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3". Biochemistry. 41 (40): 11963–71. doi: 10.1021/bi026400b. PMID  12356296.
  23. ^ a b c d Rauer H, Pennington M, Cahalan M, Chandy KG (July 1999). "Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin". The Journal of Biological Chemistry. 274 (31): 21885–92. doi: 10.1074/jbc.274.31.21885. PMID  10419508.
  24. ^ Stehling EG, Sforça ML, Zanchin NI, Oyama S, Pignatelli A, Belluzzi O, Polverini E, Corsini R, Spisni A, Pertinhez TA (March 2012). "Looking over toxin-K(+) channel interactions. Clues from the structural and functional characterization of α-KTx toxin Tc32, a Kv1.3 channel blocker". Biochemistry. 51 (9): 1885–94. doi: 10.1021/bi201713z. hdl: 11381/2435205. PMID  22332965.
  25. ^ a b Middleton RE, Sanchez M, Linde AR, Bugianesi RM, Dai G, Felix JP, Koprak SL, Staruch MJ, Bruguera M, Cox R, Ghosh A, Hwang J, Jones S, Kohler M, Slaughter RS, McManus OB, Kaczorowski GJ, Garcia ML (November 2003). "Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile". Biochemistry. 42 (46): 13698–707. doi: 10.1021/bi035209e. PMID  14622016.
  26. ^ Aiyar J, Rizzi JP, Gutman GA, Chandy KG (December 1996). "The signature sequence of voltage-gated potassium channels projects into the external vestibule". The Journal of Biological Chemistry. 271 (49): 31013–6. doi: 10.1074/jbc.271.49.31013. PMID  8940091.
  27. ^ a b c Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG (March 2003). "A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes". The Journal of Biological Chemistry. 278 (11): 9928–37. doi: 10.1074/jbc.M212868200. PMID  12511563.
  28. ^ a b c d e f g h i j k Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP (September 2012). "Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease". The Journal of Pharmacology and Experimental Therapeutics. 342 (3): 642–53. doi: 10.1124/jpet.112.191890. PMC  3422530. PMID  22637724.
  29. ^ a b c d e Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG (March 2012). "Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases". Toxicon. 59 (4): 529–46. doi: 10.1016/j.toxicon.2011.07.016. PMC  3397671. PMID  21867724.
  30. ^ a b Rashid MH, Heinzelmann G, Huq R, Tajhya RB, Chang SC, Chhabra S, Pennington MW, Beeton C, Norton RS, Kuyucak S (November 2013). "A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation". PLOS ONE. 8 (11): e78712. Bibcode: 2013PLoSO...878712R. doi: 10.1371/journal.pone.0078712. PMC  3820677. PMID  24244345.
  31. ^ a b c Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG (September 2014). "Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases". FASEB Journal. 28 (9): 3952–64. doi: 10.1096/fj.14-251967. PMC  4139903. PMID  24891519.
  32. ^ a b McNeilly TN, Frew D, Burgess ST, Wright H, Bartley DJ, Bartley Y, Nisbet AJ (August 2017). "Niche-specific gene expression in a parasitic nematode; increased expression of immunomodulators in Teladorsagia circumcincta larvae derived from host mucosa". Scientific Reports. 7 (1): 7214. Bibcode: 2017NatSR...7.7214M. doi: 10.1038/s41598-017-07092-0. PMC  5543109. PMID  28775251.
  33. ^ Edwards W, Fung-Leung WP, Huang C, Chi E, Wu N, Liu Y, Maher MP, Bonesteel R, Connor J, Fellows R, Garcia E, Lee J, Lu L, Ngo K, Scott B, Zhou H, Swanson RV, Wickenden AD (August 2014). "Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life". The Journal of Biological Chemistry. 289 (33): 22704–14. doi: 10.1074/jbc.M114.568642. PMC  4132777. PMID  24939846.
  34. ^ Wang RE, Wang Y, Zhang Y, Gabrelow C, Zhang Y, Chi V, Fu Q, Luo X, Wang D, Joseph S, Johnson K, Chatterjee AK, Wright TM, Nguyen-Tran VT, Teijaro J, Theofilopoulos AN, Schultz PG, Wang F (October 2016). "Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant". Proceedings of the National Academy of Sciences of the United States of America. 113 (41): 11501–11506. Bibcode: 2016PNAS..11311501W. doi: 10.1073/pnas.1612803113. PMC  5068325. PMID  27663736.
  35. ^ a b Zhang H, Du M, Xie J, Liu X, Sun J, Wang W, Xin X, Possani LD, Yea K, Lerner RA (August 2016). "Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries". Angewandte Chemie. 55 (32): 9306–10. doi: 10.1002/anie.201603052. PMID  27197631.
  36. ^ Jin L, Boyd BJ, White PJ, Pennington MW, Norton RS, Nicolazzo JA (February 2015). "Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases". Journal of Controlled Release. 199: 37–44. doi: 10.1016/j.jconrel.2014.12.001. PMID  25482338.
  37. ^ Jin L, Zhou QT, Chan HK, Larson IC, Pennington MW, Morales RA, Boyd BJ, Norton RS, Nicolazzo JA (February 2016). "Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases". Journal of Pharmaceutical Sciences. 105 (2): 650–656. doi: 10.1016/j.xphs.2015.10.025. PMID  26869426.
  38. ^ WO 2015013330, Iadonato & Munoz, "Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof" 
  39. ^ WO 2016112208, Iadonato; Tarcha & Lustig, "Topical applications of kv1.3 channel blocking peptides to treat skin inflammation" 
  40. ^ a b c d e f g h i j Cahalan MD, Chandy KG (September 2009). "The functional network of ion channels in T lymphocytes". Immunological Reviews. 231 (1): 59–87. doi: 10.1111/j.1600-065x.2009.00816.x. PMC  3133616. PMID  19754890.
  41. ^ a b c d e f g h i Feske S, Wulff H, Skolnik EY (March 2015). "Ion channels in innate and adaptive immunity". Annual Review of Immunology. 33 (1): 291–353. doi: 10.1146/annurev-immunol-032414-112212. PMC  4822408. PMID  25861976.
  42. ^ a b Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A, Fischer PA, Springer MS, Sigal NH, Slaughter RS, Garcia ML (March 1993). "Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation". The Journal of Experimental Medicine. 177 (3): 637–45. doi: 10.1084/jem.177.3.637. PMC  2190940. PMID  7679705.
  43. ^ a b Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S (August 1984). "Voltage-gated potassium channels are required for human T lymphocyte activation". The Journal of Experimental Medicine. 160 (2): 369–85. doi: 10.1084/jem.160.2.369. PMC  2187449. PMID  6088661.
  44. ^ Leonard RJ, Garcia ML, Slaughter RS, Reuben JP (November 1992). "Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin". Proceedings of the National Academy of Sciences of the United States of America. 89 (21): 10094–8. Bibcode: 1992PNAS...8910094L. doi: 10.1073/pnas.89.21.10094. PMC  50284. PMID  1279670.
  45. ^ Defarias FP, Stevens SP, Leonard RJ (1995). "Stable expression of human Kv1.3 potassium channels resets the resting membrane potential of cultured mammalian cells". Receptors & Channels. 3 (4): 273–81. PMID  8834000.
  46. ^ Verheugen JA, Vijverberg HP, Oortgiesen M, Cahalan MD (June 1995). "Voltage-gated and Ca(2+)-activated K+ channels in intact human T lymphocytes. Noninvasive measurements of membrane currents, membrane potential, and intracellular calcium". The Journal of General Physiology. 105 (6): 765–94. doi: 10.1085/jgp.105.6.765. PMC  2216960. PMID  7561743.
  47. ^ a b c d e f g Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–13. doi: 10.1172/jci16921. PMC  156104. PMID  12782673.
  48. ^ a b c d e f g Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA (October 2007). "Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes". Journal of Immunology. 179 (7): 4563–70. doi: 10.4049/jimmunol.179.7.4563. PMID  17878353.
  49. ^ a b c d Chiang EY, Li T, Jeet S, Peng I, Zhang J, Lee WP, DeVoss J, Caplazi P, Chen J, Warming S, Hackos DH, Mukund S, Koth CM, Grogan JL (March 2017). "Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions". Nature Communications. 8: 14644. Bibcode: 2017NatCo...814644C. doi: 10.1038/ncomms14644. PMC  5337993. PMID  28248292.
  50. ^ Fung-Leung WP, Edwards W, Liu Y, Ngo K, Angsana J, Castro G, Wu N, Liu X, Swanson RV, Wickenden AD (2017-01-20). "T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers". PLOS ONE. 12 (1): e0170102. Bibcode: 2017PLoSO..1270102F. doi: 10.1371/journal.pone.0170102. PMC  5249144. PMID  28107393.
  51. ^ Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ (July 2000). "Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis". Journal of Immunology. 165 (2): 1138–45. doi: 10.4049/jimmunol.165.2.1138. PMID  10878393.
  52. ^ Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R (October 2001). "CD4+CD28- costimulation-independent T cells in multiple sclerosis". The Journal of Clinical Investigation. 108 (8): 1185–94. doi: 10.1172/jci12516. PMC  209525. PMID  11602626.
  53. ^ García de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M (March 2004). "Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells". Journal of Clinical Immunology. 24 (2): 185–96. doi: 10.1023/B:JOCI.0000019784.20191.7f. PMID  15024186. S2CID  12368149.
  54. ^ a b c d e f Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD (October 2008). "Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block". Immunity. 29 (4): 602–14. doi: 10.1016/j.immuni.2008.07.015. PMC  2732399. PMID  18835197.
  55. ^ Khanna R, Roy L, Zhu X, Schlichter LC (April 2001). "K+ channels and the microglial respiratory burst". American Journal of Physiology. Cell Physiology. 280 (4): C796–806. doi: 10.1152/ajpcell.2001.280.4.C796. PMID  11245596. S2CID  12094438.
  56. ^ Fordyce CB, Jagasia R, Zhu X, Schlichter LC (August 2005). "Microglia Kv1.3 channels contribute to their ability to kill neurons". The Journal of Neuroscience. 25 (31): 7139–49. doi: 10.1523/jneurosci.1251-05.2005. PMC  6725234. PMID  16079396.
  57. ^ Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H (January 2017). "Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia". Glia. 65 (1): 106–121. doi: 10.1002/glia.23078. PMC  5113690. PMID  27696527.
  58. ^ Nguyen HM, Blomster LV, Christophersen P, Wulff H (July 2017). "Potassium channel expression and function in microglia: Plasticity and possible species variations". Channels. 11 (4): 305–315. doi: 10.1080/19336950.2017.1300738. PMC  5555259. PMID  28277939.
  59. ^ Rangaraju S, Raza SA, Pennati A, Deng Q, Dammer EB, Duong D, Pennington MW, Tansey MG, Lah JJ, Betarbet R, Seyfried NT, Levey AI (June 2017). "A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation". Journal of Neuroinflammation. 14 (1): 128. doi: 10.1186/s12974-017-0906-6. PMC  5485721. PMID  28651603.
  60. ^ Rangaraju S, Gearing M, Jin LW, Levey A (2015-01-01). "Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease". Journal of Alzheimer's Disease. 44 (3): 797–808. doi: 10.3233/jad-141704. PMC  4402159. PMID  25362031.
  61. ^ Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW (February 2018). "Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept". Brain. 141 (2): 596–612. doi: 10.1093/brain/awx346. PMC  5837198. PMID  29272333.
  62. ^ Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E (November 2001). "Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis". Proceedings of the National Academy of Sciences of the United States of America. 98 (24): 13942–7. Bibcode: 2001PNAS...9813942B. doi: 10.1073/pnas.241497298. PMC  61146. PMID  11717451.
  63. ^ a b c d Tsang SW, Nguyen CQ, Hall DH, Chow KL (December 2007). "mab-7 encodes a novel transmembrane protein that orchestrates sensory ray morphogenesis in C. elegans" (PDF). Developmental Biology. 312 (1): 353–66. doi: 10.1016/j.ydbio.2007.09.037. PMID  17959165.
  64. ^ a b Harris RA (January 1984). "Differential effects of membrane perturbants on voltage-activated sodium and calcium channels and calcium-dependent potassium channels". Biophysical Journal. 45 (1): 132–4. Bibcode: 1984BpJ....45..132H. doi: 10.1016/s0006-3495(84)84137-5. PMC  1435273. PMID  19431539.
  65. ^ Tanner MR, Tajhya RB, Huq R, Gehrmann EJ, Rodarte KE, Atik MA, Norton RS, Pennington MW, Beeton C (July 2017). "Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog". Clinical Immunology. 180: 45–57. doi: 10.1016/j.clim.2017.03.014. PMC  5484050. PMID  28389388.
  66. ^ a b c d Olsen C, Lustig K, Iadonato S, Tarcha E, Guttman-Yassky E (2017). "695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model". Journal of Investigative Dermatology. 137 (5): S119. doi: 10.1016/j.jid.2017.02.718.
  67. ^ Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, Xu H, Workman CT, Scheipers P, Svitacheva N, Labuda T, Krueger JG, Suárez-Fariñas M, Kabashima K, Guttman-Yassky E (February 2017). "Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling". The Journal of Allergy and Clinical Immunology. 139 (2): 562–571. doi: 10.1016/j.jaci.2016.08.029. PMID  27702671.
  68. ^ Martel BC, Lovato P, Bäumer W, Olivry T (September 2017). "Translational Animal Models of Atopic Dermatitis for Preclinical Studies". The Yale Journal of Biology and Medicine. 90 (3): 389–402. PMC  5612183. PMID  28955179.
  69. ^ a b Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H (June 2007). "Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis". The Journal of Investigative Dermatology. 127 (6): 1419–29. doi: 10.1038/sj.jid.5700717. PMC  1929164. PMID  17273162.
  70. ^ a b Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, Yasui K (December 2013). "Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model". Clinical and Experimental Dermatology. 38 (8): 897–903. doi: 10.1111/ced.12097. PMID  24252082.
  71. ^ Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, Sanchez M, McManus OB, Sirotina-Meisher A, Fischer P, Boltz RC, Goetz MA, Baker R, Bao J, Kayser F, Rupprecht KM, Parsons WH, Tong XC, Ita IE, Pivnichny J, Vincent S, Cunningham P, Hora D, Feeney W, Kaczorowski G (November 1999). "Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels". Cellular Immunology. 197 (2): 99–107. doi: 10.1006/cimm.1999.1569. PMID  10607427.
  72. ^ Hubball AW, Lang B, Souza MA, Curran OD, Martin JE, Knowles CH (August 2012). "Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility)". Neurogastroenterology and Motility. 24 (8): 719–28, e344. doi: 10.1111/j.1365-2982.2012.01924.x. PMID  22591165. S2CID  24100663.
  73. ^ Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E (January 2001). "Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation". Journal of Immunology. 166 (2): 936–44. doi: 10.4049/jimmunol.166.2.936. PMID  11145670.
  74. ^ Varga Z, Gurrola-Briones G, Papp F, Rodríguez de la Vega RC, Pedraza-Alva G, Tajhya RB, Gaspar R, Cardenas L, Rosenstein Y, Beeton C, Possani LD, Panyi G (September 2012). "Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells". Molecular Pharmacology. 82 (3): 372–82. doi: 10.1124/mol.112.078006. PMC  3422703. PMID  22622363.
  75. ^ Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP (December 2014). "Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model". Journal of Autoimmunity. 55: 63–72. doi: 10.1016/j.jaut.2014.07.003. PMC  4398058. PMID  25175978.
  76. ^ Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A (January 2011). "The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model". The Journal of Investigative Dermatology. 131 (1): 118–24. doi: 10.1038/jid.2010.245. PMID  20739949.
  77. ^ a b c d e Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG (June 2013). "Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance". Proceedings of the National Academy of Sciences of the United States of America. 110 (24): E2239–48. Bibcode: 2013PNAS..110E2239U. doi: 10.1073/pnas.1221206110. PMC  3683782. PMID  23729813.
  78. ^ Tucker K, Overton JM, Fadool DA (August 2008). "Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice". International Journal of Obesity. 32 (8): 1222–32. doi: 10.1038/ijo.2008.77. PMC  2737548. PMID  18542083.
  79. ^ Xu J, Koni PA, Wang P, Li G, Kaczmarek L, Wu Y, Li Y, Flavell RA, Desir GV (March 2003). "The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight". Human Molecular Genetics. 12 (5): 551–9. doi: 10.1093/hmg/ddg049. PMID  12588802.
  80. ^ Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV (March 2004). "The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity". Proceedings of the National Academy of Sciences of the United States of America. 101 (9): 3112–7. Bibcode: 2004PNAS..101.3112X. doi: 10.1073/pnas.0308450100. PMC  365752. PMID  14981264.
  81. ^ a b c d e f Lioudyno MI, Birch AM, Tanaka BS, Sokolov Y, Goldin AL, Chandy KG, Hall JE, Alkire MT (October 2013). "Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics". The Journal of Neuroscience. 33 (41): 16310–22. doi: 10.1523/jneurosci.0344-13.2013. PMC  3792466. PMID  24107962.
  82. ^ Peng Y, Lu K, Li Z, Zhao Y, Wang Y, Hu B, Xu P, Shi X, Zhou B, Pennington M, Chandy KG, Tang Y (April 2014). "Blockade of Kv1.3 channels ameliorates radiation-induced brain injury". Neuro-Oncology. 16 (4): 528–39. doi: 10.1093/neuonc/not221. PMC  3956348. PMID  24305723.
  83. ^ a b Yan L, Fei K, Zhang J, Dexter S, Sarras MP (January 2000). "Identification and characterization of hydra metalloproteinase 2 (HMP2): a meprin-like astacin metalloproteinase that functions in foot morphogenesis". Development. 127 (1): 129–41. doi: 10.1242/dev.127.1.129. PMID  10654607.
  84. ^ a b Guo M, Teng M, Niu L, Liu Q, Huang Q, Hao Q (April 2005). "Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold". The Journal of Biological Chemistry. 280 (13): 12405–12. doi: 10.1074/jbc.M413566200. PMID  15596436.
  85. ^ a b Koppers AJ, Reddy T, O'Bryan MK (January 2011). "The role of cysteine-rich secretory proteins in male fertility". Asian Journal of Andrology. 13 (1): 111–7. doi: 10.1038/aja.2010.77. PMC  3739402. PMID  20972450.
  86. ^ Yamazaki Y, Morita T (September 2004). "Structure and function of snake venom cysteine-rich secretory proteins". Toxicon. 44 (3): 227–31. doi: 10.1016/j.toxicon.2004.05.023. PMID  15302528.

External links

  • Overview of all the structural information available in the PDB for UniProt: P29187 (Kappa-stichotoxin-She3a) at the PDBe-KB.
Retrieved from " https://en.wikipedia.org/?title=Stichodactyla_toxin&oldid=1216074373"
This article has been published in the peer-reviewed journal WikiJournal of Science (2018). Click to view the published version.
From Wikipedia, the free encyclopedia
ShK domain-like
Rainbow colored cartoon diagram ( N-terminus = blue, C-terminus = red) of an NMR solution structure of the ShK toxin. [1] Sidechains of cysteine residues involved in disulfide linkages are displayed as sticks and the sulfur atoms in these links are colored yellow.
Identifiers
SymbolShK
Pfam PF01549
InterPro IPR003582
SMART SM00254
SCOP2 1roo / SCOPe / SUPFAM
TCDB 8.B.14
OPM superfamily 296
OPM protein 2lg4
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Kappa-stichotoxin-She3a
Identifiers
Organism Stichodactyla helianthus
Symbol?
UniProt P29187
Search for
Structures Swiss-model
Domains InterPro

Stichodactyla toxin (ShK, ShkT) is a 35-residue basic peptide from the sea anemone Stichodactyla helianthus that blocks a number of potassium channels. Related peptides form a conserved family of protein domains known as the ShkT domain. Another well-studied toxin of the family is BgK from Bunodosoma granulifera.

An analogue of ShK called ShK-186 or Dalazatide is in human trials as a therapeutic for autoimmune diseases.

History

A development timeline

Stichodactyla helianthus is a species of sea anemone (Phylum: Cnidaria) belonging to the family Stichodactylidae. Helianthus comes from the Greek words helios meaning sun, and anthos meaning flower, which corresponds to the species' common name "sun anemone". It is sessile and uses potent neurotoxins for defense against its primary predator, the spiny lobster. [2] The venom contains, among other components, numerous ion channel-blocking peptides. In 1995, a group led by Olga Castaneda and Evert Karlsson isolated ShK, a potassium channel-blocking 35-residue peptide from S. helianthus. [3] The same year, William Kem and his collaborator Michael Pennington synthesized and folded ShK, and showed it blocked neuronal and lymphocyte voltage-dependent potassium channels. [4] In 1996, Ray Norton determined the three-dimensional structure of ShK. [1] In 2005–2006, George Chandy, Christine Beeton and Michael Pennington developed ShK-170 and ShK-186 (ShK-L5), selective blockers of Kv1.3. [5] [6] ShK-186, now called Dalazatide, was advanced to human trials in 2015-2017 by Shawn Iadonato and Eric Tarcha, as the first-in-man Kv1.3 blocker for autoimmune disease. [7]

Structure

Clockwise from top-left: NMR solution structure of the ShK toxin; [1] Two views of the surface representation of ShK highlighting basic (blue) and acidic (red) residues; NMR structures of ShK-192, BmK1, MMP23-ShK, and homology model of EWSS-ShK.

ShK is cross-linked by three disulfide bridges: Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32. The solution structure of ShK reveals two short α-helices comprising residues 14-19 and 21–24; the N-terminal eight residues adopt an extended conformation, followed by a pair of interlocking turns that resemble a 310 helix; the C-terminal Cys35 residue forms a nearly head-to-tail cyclic structure through a disulfide bond with Cys3. [1] [8] [9] [10] [11] [12]

Schematic diagram of the primary structure of the ShK peptide highlighting the three disulfide (–S–S–) linkages.

Phylogenetic relationships of ShK and ShK domains

Sequence similarity tree between ShK and related peptides generated with NCBI's Constraint-based Multiple Alignment Tool (COBALT).

The SMART database at the EMBL, as of May 2018, [13] lists 3345 protein domains with structural resemblance to ShK in 1797 proteins (1 to 8 domains/protein), many in the worm Caenorhabditis elegans and venomous snakes. [14] [15] [16] [17] [18] The majority of these domains are in metallopeptidases, whereas others are in prolyl 4-hydroxylases, tyrosinases, peroxidases, oxidoreductases, or proteins containing epidermal growth factor-like domains, thrombospondin-type repeats, or trypsin-like serine protease domains. [14] [15] [16] [17] [18] The only human proteins containing ShK-like domains are MMP-23 (matrix metalloprotease 23) and MFAP-2 (microfibril-associated glycoprotein 2). [14] [15] [16] [17] [18]

Channel targets

Docking configuration of EWSS-ShK in Kv1.3. For clarity, only two of the four Kv1.3 subunits in the tetramer are shown. Lys22 is shown protruding into the pore and interacting with the channel's selectivity filter.

The ShK peptide blocks potassium (K+) ion channels Kv1.1, Kv1.3, Kv1.6, Kv3.2 and KCa3.1 with nanomolar to picomolar potency, and has no effect on the HERG ( Kv11.1) cardiac potassium channel. [19] [20] The neuronal Kv1.1 channel and the T lymphocyte Kv1.3 channel are most potently inhibited by ShK. [8]

Binding configuration in K+ channels

ShK and its analogues are blockers of the channel pore. They bind to all four subunits in the K+ channel tetramer by interacting with the shallow 'vestibule' at the outer entrance to the channel pore. [5] [8] [9] [12] [21] [22] [19] These peptides are anchored in the external vestibule by two key interactions. The first is Lys22, which protrudes into and occludes the channel's pore like a "cork in a bottle" and blocks the passage of potassium ions through the channel pore. [8] [23] [22] [19] The second is the neighboring Tyr23, which together with Lys22 forms a “functional dyad” required for channel block. [8] [9] [22] [23] [19] Many K+ channel-blocking peptides contain such a dyad of a lysine and a neighboring aromatic or aliphatic residue. [19] [20] Some K+ channel-blocking peptides lack the functional dyad, but even in these peptides a lysine physically blocks the channel, regardless of the position of the lysine in the peptide sequence. [24] Additional interactions anchor ShK and its analogues in the external vestibule and contribute to potency and selectivity. [8] [9] [22] [23] [19] For example, Arg11 and Arg29 in ShK interact with two Asp386 residues in adjacent subunits in the mouse Kv1.3 external vestibule (corresponds to Asp433 in human Kv1.3). [8] [9] [22] [23] [19]

IC50 values for block of potassium channels by ShK and related peptides. ND = not done.
Channel ShK(IC50) ShK-186
(IC50) 		ShK-192
(IC50) 		ShK-EWSS
(IC50) 		ShK-F6CA (IC50) ShK-198 (IC50) MMP-23 ShK domain (IC50)
Kv1.1 16-28 pM 7 nM 22 nM 5.4 nM 4 nM 159 pM 49 μM
Kv1.2 10 nM 48 nM ND >100 nM >100 nM ND >100 μM
Kv1.3 10-16 pM 70 pM 140 pM 34 pM 48 pM 41 pM 2.8 μM
Kv1.6 200 pM 18 nM 10.6 nM ND ND ND 400 nM
Kv3.2 5 nM 20 nM 4.2 nM ND ND ND 49 μM
KCa3.1 30 nM 115 nM >100 nM >100 nM ND ND >100 μM

Analogues that block the Kv1.3 channel

Several ShK analogues have been generated to enhance specificity for the Kv1.3 channel over the neuronal Kv1.1 channel and other closely related channels.

  • ShK-Dap22: This was the first analogue that showed some degree of specificity for Kv1.3. The pore-occluding lysine22 of ShK is replaced by diaminopropionic acid (Dap) in ShK-Dap22. [8] [22] [25] Dap is a non-natural lysine analogue with a shorter side chain length (2.5 Å from Cα) than lysine (6.3 Å). [26] Dap22 interacts with residues further out in the external vestibule in contrast to lysine22, which interacts with the channel's selectivity filter. [22] As a consequence, the orientations of ShK and ShK-Dap22 in the external vestibule are significantly different. [22] ShK-Dap22 exhibits >20-fold selectivity for Kv1.3 over closely related channels in whole-cell patch clamp experiments, [8] but in equilibrium binding assays it binds Kv1.1-Kv1.2 heterotetramers with almost the same potency as ShK, which is not predicted from the study of homotetrameric Kv1.1 or Kv1.2 channels. [25]
  • ShK-F6CA: Attaching a fluorescein to the N-terminus of the peptide via a hydrophilic AEEA linker (2-aminoethoxy-2-ethoxy acetic acid; mini-PEG) resulted in a peptide, ShK-F6CA (fluorescein-6-carboxyl), with 100-fold specificity for Kv1.3 over Kv1.1 and related channels. [27] Attachment of a tetramethylrhodamine or a biotin via the AEEA linker to ShK's N-terminus did not increase specificity for Kv1.3 over Kv1.1. [27] The enhanced specificity of ShK-F6CA might be explained by differences in charge: F6CA is negatively charged; tetramethylrhodamine is positively charged; and biotin is neutral. [27] Subsequent studies with other analogues suggest that the negatively charged F6CA likely interacts with residues on the turret of the Kv1.3 channel as shown for ShK-192 and ShK-EWSS. [9] [12]
  • ShK-170, ShK-186, ShK-192 and ShK-EWSS: Based on ShK-F6CA, additional analogues were made. Attaching a L- phosphotyrosine to the N-terminus of ShK via an AEEA linker resulted in a peptide, ShK-170, with 100-1000-fold specificity for Kv1.3 over related channels. ShK-186 (a.k.a. SL5; a.k.a. Dalazatide) is identical to ShK-170 except the C-terminal carboxyl is replaced by an amide. ShK-186 blocks Kv1.3 with an IC50 of 69 pM and exhibits the same specificity for Kv1.3 over closely related channels as ShK-170. [19] The L-phosphotyrosine of ShK-170 and ShK-186 rapidly gets dephosphorylated in vivo generating an analogue, ShK-198, with reduced specificity for Kv1.3. [5] [28] [29] To overcome this problem, ShK-192 and ShK-EWSS were developed. In ShK-192, the N-terminal L-phosphotyrosine is replaced by a non-hydrolyzable para-phosphonophenylalanine (Ppa), and Met21 is replaced by the non-natural amino acid norleucine to avoid methionine oxidation. [9] [29] In ShK-EWSS, the AEEA linker and L-phosphotyrosine are replaced by the residues glutamic acid (E), tryptophan (W) and two serines (S). [12] Both ShK-192 and ShK-EWSS are highly specific for Kv1.3 over related channels.
  • ShK-K18A: Docking and molecular dynamics simulations on Kv1.3 and Kv1.1 followed by umbrella sampling simulations, paved the way to the selective Kv1.3 inhibitor ShK-K18A. [30]
  • ShK-related peptides in parasitic worms: AcK1, a 51-residue peptide from hookworms Ancylostoma caninum and Ancylostoma ceylanicum, and BmK1, the C-terminal domain of a metalloprotease from filarial worm Brugia malayi, adopt helical structures closely resembling ShK. [31] AcK1 and BmK1 block Kv1.3 channels at nanomolar-micromolar concentrations, and they suppress rat effector memory T cells without affecting naïve and central memory T cell subsets. [31] Further, they suppress IFN-g production by human T cells and they inhibit the Delayed-type hypersensitivity response caused by skin-homing effector memory T cells. [31] Teladorsagia circumcincta is an economically important parasite that infects sheep and goats. TcK6, a 90-residue protein with a C-terminal ShK-related domain, is upregulated during the mucosal dwelling larval stage of this parasite. [32] TcK6 causes modest suppression of thapsigargin-triggered IFN-g production by sheep T cells, suggesting that the parasite use this protein for immune evasion by modulating mucosal T cells. [32]

Extending circulating half-life

Due to their low molecular mass, ShK and its analogues are prone to rapid renal elimination. In rats, the half-life is ~6 min for ShK-186 and ~11 min for ShK-198, with a clearance rate of ~950 ml/kg·min. [28] In monkeys, the half-life is ~12 min for ShK-186 and ~46 min for ShK-198, with a clearance rate of ~80 ml/kg·min. [28]

PEGylation of ShK: Conjugation of polyethylene glycol (PEG) to ShK[Q16K], an ShK analogue, increased its molecular mass and thereby reduced renal clearance and extended plasma half-life to 15 h in mice and 64 h in cynomolgus monkeys. [11] PEGylation can also decrease immunogenicity and protect a peptide from proteolysis and non-specific adsorption to inert surfaces. PEGylated ShK[Q16K] prevented adoptive-transfer experimental autoimmune encephalomyelitis in rats, a model for multiple sclerosis. [11]

  • Conjugation of ShK to larger proteins: The circulating half-life of peptides can be prolonged by coupling them to larger proteins or protein domains. [19] [33] [34] By screening a combinatorial ShK peptide library, novel analogues were identified, which when fused to the C-termini of IgG1-Fc retained picomolar potency, effectively suppressed in vivo delayed type hypersensitivity and exhibited a prolonged circulating half-life. [35]
  • Prolonged effects despite rapid plasma clearance: SPECT/CT imaging studies with a 111In-DOTA-conjugate of ShK-186 in rats and squirrel monkeys revealed a slow release from the injection site and blood levels above the channel blocking dose for 2 and 7 days, respectively. [28] Studies on human peripheral blood T cells showed that a brief exposure to ShK-186 was sufficient to suppress cytokine responses. [28] These findings suggest that ShK-186, despite its short circulating half-life, may have a prolonged therapeutic effect. In rats, the peptide is effective in treating disease in animal models of autoimmune diseases when administered once a day to once in 3 days. [28] In humans, subcutaneous injections twice a week are sufficient to ameliorate disease in patients with plaque psoriasis. [7]

Peptide delivery

The low molecular mass of ShK and its analogues, combined with their high isoelectric points, makes it unlikely that these peptides will be absorbed from the stomach or intestine following oral administration. Sub-lingual delivery is a possibility. A fluorescent ShK analogue was absorbed into the blood stream at pharmacological concentrations following sublingual administration with a mucoadhesive chitosan-based gel, with or without the penetration enhancer cetrimide. [36] Delivery of the peptide as an aerosol through the lung, or across the skin, or as eye drops are also possibilities. [37] [38] [39]

Modulation of T cell function

Expression of Kv1.3 and KCa3.1 channels during T cell activation and memory T cell generation. The numbers represent functional channel numbers per T cell determined by whole cell patch clamp. The effect of specific blockade of Kv1.3 or KCa3.1 on T cell proliferation is shown. TCM = Central memory T cell. TEM = Effector memory T cell. TEMRA = Effector memory T cell that has reacquired CD45RA.

During T cell-activation, calcium enters lymphocytes through store-operated CRAC channels (calcium release activated channel) formed as a complex of Orai and Stim proteins. [40] [41] The rise in intracellular calcium initiates a signaling cascade culminating in cytokine production and proliferation. [40] [41] The Kv1.3 K+ channel and the calcium-activated KCa3.1 K+ channel in T cells promote calcium entry into the cytoplasm through CRAC by providing a counterbalancing cation efflux. [19] [40] [41] Blockade of Kv1.3 depolarizes the membrane potential of T cells, suppresses calcium signaling and IL-2 production, but not IL2-receptor expression. [42] [43] [44] [45] [46] Kv1.3 blockers have no effect on activation pathways that are independent of a rise in intracellular calcium (e.g. anti-CD28, IL-2). [42] [43] Expression of the Kv1.3 and KCa3.1 channels varies during T cell activation and differentiation into memory T cells. [19] [40] [41] [47] [48] When naïve T cells and central memory T cells (TCM) are activated they upregulate KCa3.1 expression to ~500 per cell without significant change in Kv1.3 numbers. [19] [40] [41] [47] [48] In contrast, when terminally differentiated effector memory subsets (TEM, TEMRA [T effector memory re-expressing CD45RA]) are activated, they upregulate Kv1.3 to 1500 per cell without changes in KCa3.1. [19] [40] [41] [47] [48] The Kv1.3 channel number increases and the KCa3.1 channel number decreases as T cells are chronically activated. [40] [41] [47] [48] [49] As a result of this differential expression, blockers of KCa3.1 channels preferentially suppress the function of naïve and TCM cells, while ShK and its analogues that selectively inhibit Kv1.3 channels preferentially suppress the function of chronically activated effector memory T cells (TEM, TEMRA). [19] [40] [41] [47] [48]

Of special interest are the large number of ShK analogues developed at Amgen that suppressed interleukin-2 and interferon gamma production by T cells. [11] This inhibitory effect of Kv1.3 blockers is partial and stimulation strength dependent, with reduced inhibitory efficacy on T cells under strengthened anti-CD3/CD28 stimulation. [50] Chronically activated CD28null effector memory T cells are implicated in autoimmune diseases (e.g. lupus, Crohn's disease, rheumatoid arthritis, multiple sclerosis). [51] [52] [53]

Blockade of Kv1.3 channels in these chronically activated T cells suppresses calcium signaling, cytokine production (interferon gamma, interleukin-2, interleukin 17), and cell proliferation. [6] [19] [29] [30] [40] [41] [47] [48] Effector memory T cells that are CD28+ are refractory to suppression by Kv1.3 blockers when they are co-stimulated by anti-CD3 and anti-CD28 antibodies, but are sensitive to suppression when stimulated by anti-CD3 antibodies alone. [48] In vivo, ShK-186 paralyzes effector-memory T cells at the site of an inflammatory delayed type hypersensitivity response and prevents these T cells from activating in the inflamed tissue. [54] In contrast, ShK-186 does not affect the homing and motility of naive and TCM cells to and within lymph nodes, most likely because these cells express the KCa3.1 channel and are therefore protected from the effect of Kv1.3 blockade. [54]

Effects on microglia

Kv1.3 plays an important role in microglial activation. [55] [56] [57] [58] ShK-223, an analogue of ShK-186, decreased lipopolysaccharide (LPS) induced focal adhesion formation by microglia, reversed LPS-induced inhibition of microglial migration, and inhibited LPS-induced upregulation of EH domain containing protein 1 (EHD1), a protein involved in microglia trafficking. [59] Increased Kv1.3 expression was reported in microglia in Alzheimer plaques. [60] Kv1.3 inhibitors may have use in the management of Alzheimer's disease, as reported in a proof-of-concept study in which a small molecule Kv1.3 blocker (PAP-1) alleviated Alzheimer's disease-like characteristics in a mouse model of AD. [61]

Efficacy of analogues in animal models of human diseases

Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis

ShK, ShK-Dap22, ShK-170 and PEGylated ShK-Q16K prevent adoptive-transfer EAE in Lewis rats, a model of multiple sclerosis. [5] [11] Since multiple sclerosis is a relapsing-remitting disease, ShK-186 and ShK-192 were evaluated in a relapsing-remitting EAE model in DA (Dark Agouti) rats. Both prevented and treated disease when administered once a day to once in three days. [54] [28] [29] Thus, Kv1.3 inhibitors are effective in treating disease in rat models of multiple sclerosis when administered alone, [11] [28] [62] [63] and therapeutic effectiveness does not appear to be compromised by compensatory over-expression of KCa3.1 channels. [49] [64]

Pristane-induced arthritis (PIA), a model for rheumatoid arthritis

ShK-186 was effective in treating PIA when administered every day or on alternate days. [5] [6] [54] [28] A scorpion toxin inhibitor of KV1.3 was also effective in this model. [65] In both these studies, blockade of Kv1.3 alone was sufficient to ameliorate disease and simultaneous blockade of KCa3.1 was not necessary as has been suggested. [49] [64]

Rat models of atopic dermatitis

Most infiltrating T-cells in skin lesions from patients with moderate-to-severe atopic dermatitis (AD) express high levels of Kv1.3, suggesting that inhibitors of Kv1.3 may be effective in treating AD. [66] Ovalbumin-induced delayed type hypersensitivity and oxazolone-induced dermatitis are considered to be models of atopic dermatitis. [66] [67] [68] [69] [70] ShK, ShK-170, ShK-186, ShK-192 and ShK-IgG-Fc were all effective in the ovalbumin-induced delayed type hypersensitivity model, [5] [6] [9] [54] [28] [29] [35] [66] [69] [70] [71] [72] [73] [74] [75] while a topical formulation of ShK-198 was effective in treating oxazolone-induced dermatitis. [66] Even where compensation by KCa3.1 channels was reported to over-ride KV1.3 block, ShK administered alone suppressed delayed type hypersensitivity significantly in 2 of 3 studies, albeit modestly. [49]

Psoriasis

Psoriasis is a severe autoimmune disease of the skin that afflicts many people worldwide. Despite the success of recent biologics in ameliorating disease, there is still a search for safe and effective drugs for psoriasis. KV1.3 inhibitors (ShK, PAP-1) have been reported to treat disease in psoriasiform (psoriasis-like) SCID (severe combined immunodeficiency) mouse model. [76] In a Phase 1b placebo-controlled clinical study in patients with plaque psoriasis, ShK-186 administered twice a week (30 or 60 mg/dose/patient) by subcutaneous injection caused improvements with a statistically significant reduction in their PASI (Psoriasis Area and Severity Index) score between baseline and day 32. [7] These patients also exhibited reduced plasma levels of multiple inflammation markers and decreased expression of T cell activation markers on peripheral blood memory T cells. [7]

Diet-induced obesity and fatty liver disease

Obesity and diabetes are major healthcare problems globally. There is need for safe drugs for these metabolic diseases. In a mouse model of diet-induced obesity, ShK-186 counteracted the negative effects of increased caloric intake. It reduced weight gain, adiposity, and fatty liver; decreased blood levels of cholesterol, sugar, HbA1c, insulin, and leptin; and enhanced peripheral insulin sensitivity. [77] Genetic deletion of the Kv1.3 gene has the same effect, indicating that ShK-186's effect is due to Kv1.3 blockade. [78] [77] [79] [80] At least two mechanisms contribute to ShK-186's therapeutic benefits. The high calorie diet induced Kv1.3 expression in brown fat tissues. [77] By blocking Kv1.3, ShK-186 doubled glucose uptake and increased β-oxidation of fatty acids, glycolysis, fatty acid synthesis and uncoupling protein 1 expression by brown fat. [77] As a consequence of brown fat activation, oxygen consumption and energy expenditure were augmented. [77] The obesity diet also induced Kv1.3 expression in the liver, and ShK-186 caused profound alterations in energy and lipid metabolism in the liver. ShK, its analogues or other Kv1.3 blockers may have use in controlling the negative consequences of high calorie diets.

Arousal and anesthesia

The mechanisms of general anesthesia involve multiple molecular targets and pathways that are not completely understood. [81] Sevoflurane is a common anesthetic used to induce general anesthesia during surgery. [81] Rats continually exposed to sevoflurane lose their righting reflex as an index of loss of consciousness. In these rats, microinfusion of ShK into the central medial thalamic nucleus (CMT) reversed sevoflurane-induced anesthesia in rodents. [81] ShK-treated rats righted themselves fully (restored consciousness) despite being continually exposed to sevoflurane. [81] ShK-microinfusion into neighboring regions of the brain did not have this effect. [81] Sevoflurane enhanced potassium currents in the CMT, while ShK and ShK-186 countered this effect. [81] These studies suggest that ShK-sensitive K+ channels in the CMT are important for suppressing arousal during anesthesia.

Preventing brain damage following therapeutic brain radiation

Brain radiation is used to treat tumors of the head, neck, and brain, but this treatment carries a significant risk of neurologic injury. Injury is, in part, due to the activation of microglia and microglia-mediated damage of neurons. Neuroprotective therapies for radiation-induced brain injury are still limited. In a mouse model of brain radiation, ShK-170 reversed neurological deficits, and protected neurons from radiation-induced brain injury by suppressing microglia. [82]

Toxicity of ShK and its analogues

ShK and ShK-Dap22

ShK peptide has a low toxicity profile in mice. ShK is effective in treating autoimmune diseases at 10 to 100 mg/kg bodyweight. It has a median paralytic dose of approximately 25 mg/kg bodyweight (250-2500 higher than the pharmacological dose). In rats the therapeutic safety index is greater than 75-fold. ShK-Dap22 displayed a lower toxicity profile. [8] A 1.0 mg dose did not induce any hyperactivity, seizures or mortality in rats. The median paralytic dose for ShK-Dap22 is about 200 mg/kg bodyweight (2000-20000 higher than pharmacological dose). [8] PEGylated ShK[Q16K] showed no adverse toxicity in monkeys over a period of several months. [11]

ShK-186/Dalazatide

ShK-186 also displays a low toxicity profile in rats. Daily administration of ShK-170 or ShK-186 (100 µg/kg/day) by subcutaneous injection over 4 weeks in rats does not induce any changes in blood counts, blood chemistry or histopathology. [5] [6] [28] By virtue of suppressing only TEM and TEMRA cells, ShK-186 did not compromise protective immune responses to influenza virus and chlamydial infection in rats, most likely because naïve and TCM cells unaffected by Kv1.3 blockade mounted effective immune responses. [54] ShK-186 is poorly immunogenic and did not elicit anti-ShK antibodies in rats repeatedly administered the peptide. [6] This is possibly because the peptide's disulfide-bonded structure hinders processing and antigen presentation by antigen-presenting cells. ShK-186 also shares sequence and structural similarity to a ShK-like domain in matrix metalloprotease 23, [14] [15] [16] [17] [18] which may cause the immune system to assume it is a normal protein in the body. ShK-186 was safe in non-human primates. In Phase 1a and 1b trials in healthy human volunteers, ShK-186 was well tolerated, no grade 3 or 4 adverse effects or laboratory abnormalities were noted, and the predicted range of drug exposures were achieved. [7] The most common adverse events were temporary mild (Grade 1) hypoesthesia and paresthesia involving the hands, feet, or perioral area. Mild muscle spasms, sensitivity of teeth, and injection site pain were also observed. [7]

Functions of ShK-like proteins

MMP-23

MMP-23 belongs to the family of zinc- and calcium-dependent matrix metalloproteases. It is anchored in the cell membrane by an N-terminal prodomain, and it contains three extracellular domains: catalytic metalloprotease domain, ShK domain and immunoglobulin-like cell adhesion molecule ( Ig-CaM) domain. [14] [15] [16] [17] [18] The prodomain traps the voltage-gated potassium channel KV1.3, but not the closely related KV1.2 channel, in the endoplasmic reticulum. [14] [15] [16] [17] Studies with chimeras suggest that the prodomain interacts with the KV1.3 region from the S5 transmembrane segment to the C terminus. [14] [15] [16] [17] NMR studies of the prodomain reveal a single trans-membrane alpha-helix, joined by a short linker to a juxta-membrane alpha-helix, which is associated with the surface of the membrane. [14] [15] [16] [17] The prodomain shares topological similarity with proteins (KCNE1, KCNE2, KCNE4) known to trap potassium channels in the secretory pathway, suggesting a shared mechanism of channel regulation. [14] [15] [16] [17] MMP-23's catalytic domain displays structural homology with catalytic domains in other metalloproteases, and likely functions as an endopeptidase. MMP-23's ShK domain lies immediately after the catalytic domain and is connected to the IgCAM domain by a short proline-rich linker. It shares phylogenetic relatedness to sea anemone toxins and ICR-CRISP domains, being most similar to the BgK toxin from sea anemone Bunodosoma granulifera. [14] [15] [16] [17] This ShK domain blocks voltage-gated potassium channels (KV1.6 > KV1.3 > KV1.1 = KV3.2 > Kv1.4, in decreasing potency) in the nanomolar to low micromolar range. [14] KV1.3 is required for sustaining calcium signaling during activation of human T cells. [19] [40] [47] By trapping KV1.3 in the endoplasmic reticulum via the prodomain, and by blocking the KV1.3 channel with the ShK domain, MMP-23 may serve as an immune checkpoint to reduce excessive T cell activation during an immune response. In support, increased expression of MMP-23 in melanoma cancer cells decreases tumor-infiltrating lymphocytes, and is associated with cancer recurrence and shorter periods of progression-free survival. [17] However, in melanomas, expression of MMP-23 does not correlate with Kv1.3 expression, suggesting that MMP-23's deleterious effect in melanomas may not be connected with its Kv1.3 channel-modulating function. [17] MMP-23's C-terminal IgCAM domain shares sequence similarity with IgCAM domains in proteins known to mediate protein-protein and protein-lipid interactions (e.g. CDON, human Brother of CDO, ROBO1-4, hemicentin, NCAM1 and NCAM2). [14] [15] [16] [17] In summary, the four domains of MMP-23 may work synergistically to modulate immune responses in vivo.

Mab7

In male Caenorhabditis elegans worms, the absence of a protein called Mab7 ( Q95Q39) results in malformed sensory rays that are required for mating. [63] Introduction of Mab7 into these male worms restores normal development of normal sensory rays. [63] Introduction of Mab7 proteins lacking the ShK domain does not correct the defect of sensory rays, suggesting a role for the ShK-domain of Mab7 in sensory ray development. [63]

HMP2 and PMP1

HMP2 and PMP-1 are astacin metalloproteinases from the Cnidarian Hydra vulgaris and the jellyfish Podocoryne carnea that contain ShK-like domains at their C-termini. [83] [17] Both these ShK-domains contain the critical pore-occluding lysine required for K+ channel block. [14] HMP2 plays a critical role in foot regeneration of Hydra, [83] while PMP-1 is found in the feeding organ of the jelly fish and the ShK-domain may paralyze prey after they are ingested. [17]

CRISPs

The two domains of a Cysteine-rich secretory protein (CRISP). [84] CAP-like 'Pathogenesis-related 1' domain (PR-1) in white. ShK-like 'Cysteine-Rich Domain' (CRD) in red. Disulphides in yellow. ( PDB: 1WVR​)

More distantly related are Cysteine-rich secretory proteins (CRISPs), which contain a ShK-like 'Cystine-rich domain' as well as a larger CAP-like 'Pathogenesis related 1' domain. [84] These proteins are involved in mammalian reproduction [85] as well as in the venoms of some snakes. [86] In both cases, the mechanism is believed to involve inhibition of ion channel activity. [85]

References

This article was adapted from the following source under a CC BY 4.0 license ( 2018) ( reviewer reports): Shih Chieh Chang; Saumya Bajaj; K. George Chandy (1 June 2018). "ShK toxin: history, structure and therapeutic applications for autoimmune diseases" (PDF). WikiJournal of Science. 1 (1): 3. doi: 10.15347/WJS/2018.003. ISSN  2470-6345. Wikidata  Q55120296.{{ cite journal}}: CS1 maint: unflagged free DOI ( link)

  1. ^ a b c d PDB: 1ROO​; Tudor JE, Pallaghy PK, Pennington MW, Norton RS (April 1996). "Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone". Nature Structural Biology. 3 (4): 317–20. doi: 10.1038/nsb0496-317. PMID  8599755. S2CID  9180663.
  2. ^ Norton RS, Pennington MW, Wulff H (December 2004). "Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases". Current Medicinal Chemistry. 11 (23): 3041–52. doi: 10.2174/0929867043363947. PMID  15578998.
  3. ^ Castañeda O, Sotolongo V, Amor AM, Stöcklin R, Anderson AJ, Harvey AL, Engström A, Wernstedt C, Karlsson E (May 1995). "Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus". Toxicon. 33 (5): 603–13. doi: 10.1016/0041-0101(95)00013-C. PMID  7660365.
  4. ^ Pennington MW, Byrnes ME, Zaydenberg I, Khaytin I, de Chastonay J, Krafte DS, Hill R, Mahnir VM, Volberg WA, Gorczyca W (November 1995). "Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone". International Journal of Peptide and Protein Research. 46 (5): 354–8. doi: 10.1111/j.1399-3011.1995.tb01068.x. PMID  8567178.
  5. ^ a b c d e f g Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG (April 2005). "Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases". Molecular Pharmacology. 67 (4): 1369–81. doi: 10.1124/mol.104.008193. PMC  4275123. PMID  15665253.
  6. ^ a b c d e f Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–9. Bibcode: 2006PNAS..10317414B. doi: 10.1073/pnas.0605136103. PMC  1859943. PMID  17088564.
  7. ^ a b c d e f Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP (July 2017). "Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial". PLOS ONE. 12 (7): e0180762. Bibcode: 2017PLoSO..1280762T. doi: 10.1371/journal.pone.0180762. PMC  5516987. PMID  28723914.
  8. ^ a b c d e f g h i j k Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Christian EP, Cahalan MD, Norton RS, Chandy KG (December 1998). "ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide". The Journal of Biological Chemistry. 273 (49): 32697–707. doi: 10.1074/jbc.273.49.32697. PMID  9830012.
  9. ^ a b c d e f g h Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG (April 2009). "Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes". Molecular Pharmacology. 75 (4): 762–73. doi: 10.1124/mol.108.052704. PMC  2684922. PMID  19122005.
  10. ^ Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS (November 2012). "A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3". FEBS Letters. 586 (22): 3996–4001. doi: 10.1016/j.febslet.2012.09.038. PMC  3496055. PMID  23063513.
  11. ^ a b c d e f g Murray JK, Qian YX, Liu B, Elliott R, Aral J, Park C, Zhang X, Stenkilsson M, Salyers K, Rose M, Li H, Yu S, Andrews KL, Colombero A, Werner J, Gaida K, Sickmier EA, Miu P, Itano A, McGivern J, Gegg CV, Sullivan JK, Miranda LP (September 2015). "Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3". Journal of Medicinal Chemistry. 58 (17): 6784–802. doi: 10.1021/acs.jmedchem.5b00495. PMID  26288216. S2CID  28397762.
  12. ^ a b c d Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS (June 2015). "N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3". The FEBS Journal. 282 (12): 2247–59. doi: 10.1111/febs.13294. PMC  4472561. PMID  25864722.
  13. ^ "SMART: ShKT domain annotation". smart.embl-heidelberg.de. Retrieved 2018-05-16.
  14. ^ a b c d e f g h i j k l m Rangaraju S, Khoo KK, Feng ZP, Crossley G, Nugent D, Khaytin I, Chi V, Pham C, Calabresi P, Pennington MW, Norton RS, Chandy KG (March 2010). "Potassium channel modulation by a toxin domain in matrix metalloprotease 23". The Journal of Biological Chemistry. 285 (12): 9124–36. doi: 10.1074/jbc.M109.071266. PMC  2838332. PMID  19965868.
  15. ^ a b c d e f g h i j k Nguyen HM, Galea CA, Schmunk G, Smith BJ, Edwards RA, Norton RS, Chandy KG (March 2013). "Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease". The Journal of Biological Chemistry. 288 (9): 6451–64. doi: 10.1074/jbc.M112.421495. PMC  3585079. PMID  23300077.
  16. ^ a b c d e f g h i j k Galea CA, Nguyen HM, George Chandy K, Smith BJ, Norton RS (April 2014). "Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking". Cellular and Molecular Life Sciences. 71 (7): 1191–210. doi: 10.1007/s00018-013-1431-0. PMID  23912897. S2CID  8113220.
  17. ^ a b c d e f g h i j k l m n o Moogk D, da Silva IP, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krogsgaard M (December 2014). "Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy". Journal of Translational Medicine. 12: 342. doi: 10.1186/s12967-014-0342-7. PMC  4272770. PMID  25491880.
  18. ^ a b c d e Pan T, Gröger H, Schmid V, Spring J (July 1998). "A toxin homology domain in an astacin-like metalloproteinase of the jellyfish Podocoryne carnea with a dual role in digestion and development". Development Genes and Evolution. 208 (5): 259–66. doi: 10.1007/s004270050180. PMID  9683741. S2CID  13562676.
  19. ^ a b c d e f g h i j k l m n o p Chandy KG, Norton RS (June 2017). "v1.3 channels in T cells as therapeutics for autoimmune disease". Current Opinion in Chemical Biology. 38: 97–107. doi: 10.1016/j.cbpa.2017.02.015. PMID  28412597.
  20. ^ a b Gilquin B, Braud S, Eriksson MA, Roux B, Bailey TD, Priest BT, Garcia ML, Ménez A, Gasparini S (July 2005). "A variable residue in the pore of Kv1 channels is critical for the high affinity of blockers from sea anemones and scorpions". The Journal of Biological Chemistry. 280 (29): 27093–102. doi: 10.1074/jbc.M413626200. PMID  15890656.
  21. ^ Pennington MW, Mahnir VM, Khaytin I, Zaydenberg I, Byrnes ME, Kem WR (December 1996). "An essential binding surface for ShK toxin interaction with rat brain potassium channels". Biochemistry. 35 (51): 16407–11. doi: 10.1021/bi962463g. PMID  8987971.
  22. ^ a b c d e f g h Lanigan MD, Kalman K, Lefievre Y, Pennington MW, Chandy KG, Norton RS (October 2002). "Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3". Biochemistry. 41 (40): 11963–71. doi: 10.1021/bi026400b. PMID  12356296.
  23. ^ a b c d Rauer H, Pennington M, Cahalan M, Chandy KG (July 1999). "Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin". The Journal of Biological Chemistry. 274 (31): 21885–92. doi: 10.1074/jbc.274.31.21885. PMID  10419508.
  24. ^ Stehling EG, Sforça ML, Zanchin NI, Oyama S, Pignatelli A, Belluzzi O, Polverini E, Corsini R, Spisni A, Pertinhez TA (March 2012). "Looking over toxin-K(+) channel interactions. Clues from the structural and functional characterization of α-KTx toxin Tc32, a Kv1.3 channel blocker". Biochemistry. 51 (9): 1885–94. doi: 10.1021/bi201713z. hdl: 11381/2435205. PMID  22332965.
  25. ^ a b Middleton RE, Sanchez M, Linde AR, Bugianesi RM, Dai G, Felix JP, Koprak SL, Staruch MJ, Bruguera M, Cox R, Ghosh A, Hwang J, Jones S, Kohler M, Slaughter RS, McManus OB, Kaczorowski GJ, Garcia ML (November 2003). "Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile". Biochemistry. 42 (46): 13698–707. doi: 10.1021/bi035209e. PMID  14622016.
  26. ^ Aiyar J, Rizzi JP, Gutman GA, Chandy KG (December 1996). "The signature sequence of voltage-gated potassium channels projects into the external vestibule". The Journal of Biological Chemistry. 271 (49): 31013–6. doi: 10.1074/jbc.271.49.31013. PMID  8940091.
  27. ^ a b c Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG (March 2003). "A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes". The Journal of Biological Chemistry. 278 (11): 9928–37. doi: 10.1074/jbc.M212868200. PMID  12511563.
  28. ^ a b c d e f g h i j k Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP (September 2012). "Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease". The Journal of Pharmacology and Experimental Therapeutics. 342 (3): 642–53. doi: 10.1124/jpet.112.191890. PMC  3422530. PMID  22637724.
  29. ^ a b c d e Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG (March 2012). "Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases". Toxicon. 59 (4): 529–46. doi: 10.1016/j.toxicon.2011.07.016. PMC  3397671. PMID  21867724.
  30. ^ a b Rashid MH, Heinzelmann G, Huq R, Tajhya RB, Chang SC, Chhabra S, Pennington MW, Beeton C, Norton RS, Kuyucak S (November 2013). "A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation". PLOS ONE. 8 (11): e78712. Bibcode: 2013PLoSO...878712R. doi: 10.1371/journal.pone.0078712. PMC  3820677. PMID  24244345.
  31. ^ a b c Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG (September 2014). "Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases". FASEB Journal. 28 (9): 3952–64. doi: 10.1096/fj.14-251967. PMC  4139903. PMID  24891519.
  32. ^ a b McNeilly TN, Frew D, Burgess ST, Wright H, Bartley DJ, Bartley Y, Nisbet AJ (August 2017). "Niche-specific gene expression in a parasitic nematode; increased expression of immunomodulators in Teladorsagia circumcincta larvae derived from host mucosa". Scientific Reports. 7 (1): 7214. Bibcode: 2017NatSR...7.7214M. doi: 10.1038/s41598-017-07092-0. PMC  5543109. PMID  28775251.
  33. ^ Edwards W, Fung-Leung WP, Huang C, Chi E, Wu N, Liu Y, Maher MP, Bonesteel R, Connor J, Fellows R, Garcia E, Lee J, Lu L, Ngo K, Scott B, Zhou H, Swanson RV, Wickenden AD (August 2014). "Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life". The Journal of Biological Chemistry. 289 (33): 22704–14. doi: 10.1074/jbc.M114.568642. PMC  4132777. PMID  24939846.
  34. ^ Wang RE, Wang Y, Zhang Y, Gabrelow C, Zhang Y, Chi V, Fu Q, Luo X, Wang D, Joseph S, Johnson K, Chatterjee AK, Wright TM, Nguyen-Tran VT, Teijaro J, Theofilopoulos AN, Schultz PG, Wang F (October 2016). "Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant". Proceedings of the National Academy of Sciences of the United States of America. 113 (41): 11501–11506. Bibcode: 2016PNAS..11311501W. doi: 10.1073/pnas.1612803113. PMC  5068325. PMID  27663736.
  35. ^ a b Zhang H, Du M, Xie J, Liu X, Sun J, Wang W, Xin X, Possani LD, Yea K, Lerner RA (August 2016). "Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries". Angewandte Chemie. 55 (32): 9306–10. doi: 10.1002/anie.201603052. PMID  27197631.
  36. ^ Jin L, Boyd BJ, White PJ, Pennington MW, Norton RS, Nicolazzo JA (February 2015). "Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases". Journal of Controlled Release. 199: 37–44. doi: 10.1016/j.jconrel.2014.12.001. PMID  25482338.
  37. ^ Jin L, Zhou QT, Chan HK, Larson IC, Pennington MW, Morales RA, Boyd BJ, Norton RS, Nicolazzo JA (February 2016). "Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases". Journal of Pharmaceutical Sciences. 105 (2): 650–656. doi: 10.1016/j.xphs.2015.10.025. PMID  26869426.
  38. ^ WO 2015013330, Iadonato & Munoz, "Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof" 
  39. ^ WO 2016112208, Iadonato; Tarcha & Lustig, "Topical applications of kv1.3 channel blocking peptides to treat skin inflammation" 
  40. ^ a b c d e f g h i j Cahalan MD, Chandy KG (September 2009). "The functional network of ion channels in T lymphocytes". Immunological Reviews. 231 (1): 59–87. doi: 10.1111/j.1600-065x.2009.00816.x. PMC  3133616. PMID  19754890.
  41. ^ a b c d e f g h i Feske S, Wulff H, Skolnik EY (March 2015). "Ion channels in innate and adaptive immunity". Annual Review of Immunology. 33 (1): 291–353. doi: 10.1146/annurev-immunol-032414-112212. PMC  4822408. PMID  25861976.
  42. ^ a b Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A, Fischer PA, Springer MS, Sigal NH, Slaughter RS, Garcia ML (March 1993). "Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation". The Journal of Experimental Medicine. 177 (3): 637–45. doi: 10.1084/jem.177.3.637. PMC  2190940. PMID  7679705.
  43. ^ a b Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S (August 1984). "Voltage-gated potassium channels are required for human T lymphocyte activation". The Journal of Experimental Medicine. 160 (2): 369–85. doi: 10.1084/jem.160.2.369. PMC  2187449. PMID  6088661.
  44. ^ Leonard RJ, Garcia ML, Slaughter RS, Reuben JP (November 1992). "Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin". Proceedings of the National Academy of Sciences of the United States of America. 89 (21): 10094–8. Bibcode: 1992PNAS...8910094L. doi: 10.1073/pnas.89.21.10094. PMC  50284. PMID  1279670.
  45. ^ Defarias FP, Stevens SP, Leonard RJ (1995). "Stable expression of human Kv1.3 potassium channels resets the resting membrane potential of cultured mammalian cells". Receptors & Channels. 3 (4): 273–81. PMID  8834000.
  46. ^ Verheugen JA, Vijverberg HP, Oortgiesen M, Cahalan MD (June 1995). "Voltage-gated and Ca(2+)-activated K+ channels in intact human T lymphocytes. Noninvasive measurements of membrane currents, membrane potential, and intracellular calcium". The Journal of General Physiology. 105 (6): 765–94. doi: 10.1085/jgp.105.6.765. PMC  2216960. PMID  7561743.
  47. ^ a b c d e f g Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–13. doi: 10.1172/jci16921. PMC  156104. PMID  12782673.
  48. ^ a b c d e f g Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA (October 2007). "Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes". Journal of Immunology. 179 (7): 4563–70. doi: 10.4049/jimmunol.179.7.4563. PMID  17878353.
  49. ^ a b c d Chiang EY, Li T, Jeet S, Peng I, Zhang J, Lee WP, DeVoss J, Caplazi P, Chen J, Warming S, Hackos DH, Mukund S, Koth CM, Grogan JL (March 2017). "Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions". Nature Communications. 8: 14644. Bibcode: 2017NatCo...814644C. doi: 10.1038/ncomms14644. PMC  5337993. PMID  28248292.
  50. ^ Fung-Leung WP, Edwards W, Liu Y, Ngo K, Angsana J, Castro G, Wu N, Liu X, Swanson RV, Wickenden AD (2017-01-20). "T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers". PLOS ONE. 12 (1): e0170102. Bibcode: 2017PLoSO..1270102F. doi: 10.1371/journal.pone.0170102. PMC  5249144. PMID  28107393.
  51. ^ Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ (July 2000). "Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis". Journal of Immunology. 165 (2): 1138–45. doi: 10.4049/jimmunol.165.2.1138. PMID  10878393.
  52. ^ Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R (October 2001). "CD4+CD28- costimulation-independent T cells in multiple sclerosis". The Journal of Clinical Investigation. 108 (8): 1185–94. doi: 10.1172/jci12516. PMC  209525. PMID  11602626.
  53. ^ García de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M (March 2004). "Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells". Journal of Clinical Immunology. 24 (2): 185–96. doi: 10.1023/B:JOCI.0000019784.20191.7f. PMID  15024186. S2CID  12368149.
  54. ^ a b c d e f Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD (October 2008). "Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block". Immunity. 29 (4): 602–14. doi: 10.1016/j.immuni.2008.07.015. PMC  2732399. PMID  18835197.
  55. ^ Khanna R, Roy L, Zhu X, Schlichter LC (April 2001). "K+ channels and the microglial respiratory burst". American Journal of Physiology. Cell Physiology. 280 (4): C796–806. doi: 10.1152/ajpcell.2001.280.4.C796. PMID  11245596. S2CID  12094438.
  56. ^ Fordyce CB, Jagasia R, Zhu X, Schlichter LC (August 2005). "Microglia Kv1.3 channels contribute to their ability to kill neurons". The Journal of Neuroscience. 25 (31): 7139–49. doi: 10.1523/jneurosci.1251-05.2005. PMC  6725234. PMID  16079396.
  57. ^ Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H (January 2017). "Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia". Glia. 65 (1): 106–121. doi: 10.1002/glia.23078. PMC  5113690. PMID  27696527.
  58. ^ Nguyen HM, Blomster LV, Christophersen P, Wulff H (July 2017). "Potassium channel expression and function in microglia: Plasticity and possible species variations". Channels. 11 (4): 305–315. doi: 10.1080/19336950.2017.1300738. PMC  5555259. PMID  28277939.
  59. ^ Rangaraju S, Raza SA, Pennati A, Deng Q, Dammer EB, Duong D, Pennington MW, Tansey MG, Lah JJ, Betarbet R, Seyfried NT, Levey AI (June 2017). "A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation". Journal of Neuroinflammation. 14 (1): 128. doi: 10.1186/s12974-017-0906-6. PMC  5485721. PMID  28651603.
  60. ^ Rangaraju S, Gearing M, Jin LW, Levey A (2015-01-01). "Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease". Journal of Alzheimer's Disease. 44 (3): 797–808. doi: 10.3233/jad-141704. PMC  4402159. PMID  25362031.
  61. ^ Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW (February 2018). "Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept". Brain. 141 (2): 596–612. doi: 10.1093/brain/awx346. PMC  5837198. PMID  29272333.
  62. ^ Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E (November 2001). "Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis". Proceedings of the National Academy of Sciences of the United States of America. 98 (24): 13942–7. Bibcode: 2001PNAS...9813942B. doi: 10.1073/pnas.241497298. PMC  61146. PMID  11717451.
  63. ^ a b c d Tsang SW, Nguyen CQ, Hall DH, Chow KL (December 2007). "mab-7 encodes a novel transmembrane protein that orchestrates sensory ray morphogenesis in C. elegans" (PDF). Developmental Biology. 312 (1): 353–66. doi: 10.1016/j.ydbio.2007.09.037. PMID  17959165.
  64. ^ a b Harris RA (January 1984). "Differential effects of membrane perturbants on voltage-activated sodium and calcium channels and calcium-dependent potassium channels". Biophysical Journal. 45 (1): 132–4. Bibcode: 1984BpJ....45..132H. doi: 10.1016/s0006-3495(84)84137-5. PMC  1435273. PMID  19431539.
  65. ^ Tanner MR, Tajhya RB, Huq R, Gehrmann EJ, Rodarte KE, Atik MA, Norton RS, Pennington MW, Beeton C (July 2017). "Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog". Clinical Immunology. 180: 45–57. doi: 10.1016/j.clim.2017.03.014. PMC  5484050. PMID  28389388.
  66. ^ a b c d Olsen C, Lustig K, Iadonato S, Tarcha E, Guttman-Yassky E (2017). "695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model". Journal of Investigative Dermatology. 137 (5): S119. doi: 10.1016/j.jid.2017.02.718.
  67. ^ Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, Xu H, Workman CT, Scheipers P, Svitacheva N, Labuda T, Krueger JG, Suárez-Fariñas M, Kabashima K, Guttman-Yassky E (February 2017). "Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling". The Journal of Allergy and Clinical Immunology. 139 (2): 562–571. doi: 10.1016/j.jaci.2016.08.029. PMID  27702671.
  68. ^ Martel BC, Lovato P, Bäumer W, Olivry T (September 2017). "Translational Animal Models of Atopic Dermatitis for Preclinical Studies". The Yale Journal of Biology and Medicine. 90 (3): 389–402. PMC  5612183. PMID  28955179.
  69. ^ a b Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H (June 2007). "Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis". The Journal of Investigative Dermatology. 127 (6): 1419–29. doi: 10.1038/sj.jid.5700717. PMC  1929164. PMID  17273162.
  70. ^ a b Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, Yasui K (December 2013). "Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model". Clinical and Experimental Dermatology. 38 (8): 897–903. doi: 10.1111/ced.12097. PMID  24252082.
  71. ^ Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, Sanchez M, McManus OB, Sirotina-Meisher A, Fischer P, Boltz RC, Goetz MA, Baker R, Bao J, Kayser F, Rupprecht KM, Parsons WH, Tong XC, Ita IE, Pivnichny J, Vincent S, Cunningham P, Hora D, Feeney W, Kaczorowski G (November 1999). "Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels". Cellular Immunology. 197 (2): 99–107. doi: 10.1006/cimm.1999.1569. PMID  10607427.
  72. ^ Hubball AW, Lang B, Souza MA, Curran OD, Martin JE, Knowles CH (August 2012). "Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility)". Neurogastroenterology and Motility. 24 (8): 719–28, e344. doi: 10.1111/j.1365-2982.2012.01924.x. PMID  22591165. S2CID  24100663.
  73. ^ Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E (January 2001). "Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation". Journal of Immunology. 166 (2): 936–44. doi: 10.4049/jimmunol.166.2.936. PMID  11145670.
  74. ^ Varga Z, Gurrola-Briones G, Papp F, Rodríguez de la Vega RC, Pedraza-Alva G, Tajhya RB, Gaspar R, Cardenas L, Rosenstein Y, Beeton C, Possani LD, Panyi G (September 2012). "Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells". Molecular Pharmacology. 82 (3): 372–82. doi: 10.1124/mol.112.078006. PMC  3422703. PMID  22622363.
  75. ^ Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP (December 2014). "Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model". Journal of Autoimmunity. 55: 63–72. doi: 10.1016/j.jaut.2014.07.003. PMC  4398058. PMID  25175978.
  76. ^ Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A (January 2011). "The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model". The Journal of Investigative Dermatology. 131 (1): 118–24. doi: 10.1038/jid.2010.245. PMID  20739949.
  77. ^ a b c d e Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG (June 2013). "Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance". Proceedings of the National Academy of Sciences of the United States of America. 110 (24): E2239–48. Bibcode: 2013PNAS..110E2239U. doi: 10.1073/pnas.1221206110. PMC  3683782. PMID  23729813.
  78. ^ Tucker K, Overton JM, Fadool DA (August 2008). "Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice". International Journal of Obesity. 32 (8): 1222–32. doi: 10.1038/ijo.2008.77. PMC  2737548. PMID  18542083.
  79. ^ Xu J, Koni PA, Wang P, Li G, Kaczmarek L, Wu Y, Li Y, Flavell RA, Desir GV (March 2003). "The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight". Human Molecular Genetics. 12 (5): 551–9. doi: 10.1093/hmg/ddg049. PMID  12588802.
  80. ^ Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV (March 2004). "The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity". Proceedings of the National Academy of Sciences of the United States of America. 101 (9): 3112–7. Bibcode: 2004PNAS..101.3112X. doi: 10.1073/pnas.0308450100. PMC  365752. PMID  14981264.
  81. ^ a b c d e f Lioudyno MI, Birch AM, Tanaka BS, Sokolov Y, Goldin AL, Chandy KG, Hall JE, Alkire MT (October 2013). "Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics". The Journal of Neuroscience. 33 (41): 16310–22. doi: 10.1523/jneurosci.0344-13.2013. PMC  3792466. PMID  24107962.
  82. ^ Peng Y, Lu K, Li Z, Zhao Y, Wang Y, Hu B, Xu P, Shi X, Zhou B, Pennington M, Chandy KG, Tang Y (April 2014). "Blockade of Kv1.3 channels ameliorates radiation-induced brain injury". Neuro-Oncology. 16 (4): 528–39. doi: 10.1093/neuonc/not221. PMC  3956348. PMID  24305723.
  83. ^ a b Yan L, Fei K, Zhang J, Dexter S, Sarras MP (January 2000). "Identification and characterization of hydra metalloproteinase 2 (HMP2): a meprin-like astacin metalloproteinase that functions in foot morphogenesis". Development. 127 (1): 129–41. doi: 10.1242/dev.127.1.129. PMID  10654607.
  84. ^ a b Guo M, Teng M, Niu L, Liu Q, Huang Q, Hao Q (April 2005). "Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold". The Journal of Biological Chemistry. 280 (13): 12405–12. doi: 10.1074/jbc.M413566200. PMID  15596436.
  85. ^ a b Koppers AJ, Reddy T, O'Bryan MK (January 2011). "The role of cysteine-rich secretory proteins in male fertility". Asian Journal of Andrology. 13 (1): 111–7. doi: 10.1038/aja.2010.77. PMC  3739402. PMID  20972450.
  86. ^ Yamazaki Y, Morita T (September 2004). "Structure and function of snake venom cysteine-rich secretory proteins". Toxicon. 44 (3): 227–31. doi: 10.1016/j.toxicon.2004.05.023. PMID  15302528.

External links

  • Overview of all the structural information available in the PDB for UniProt: P29187 (Kappa-stichotoxin-She3a) at the PDBe-KB.
Retrieved from " https://en.wikipedia.org/?title=Stichodactyla_toxin&oldid=1216074373"

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook




Top Of Page

Home • Search • Translate

© CSE